The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies. by Kanno, Jun et al.
Rat Uterotrophic Bioassay | Mini-Monograph
The Organisation for Economic Co-operation
and Development (OECD) initiated a high-
priority activity in 1997 to revise existing
guidelines and to develop new guidelines
for the screening and testing of potential
endocrine disrupters (OECD 1998a). This
activity is managed by a Validation
Management Group (VMG) reporting to the
Task Force on Endocrine Disrupters Testing
and Assessment as part of the OECD Test
Guidelines Programme. One portion of the
activity is to validate the rodent uterotrophic
bioassay, an in vivo screen intended to identify
compounds that are suspected agonists or
antagonists of estrogen, and to assist the prior-
itization of positive compounds for further
testing. In phase 1 of the validation program,
standardized protocols were developed for two
versions of the uterotrophic bioassay, the
immature rat and the adult ovariectomized
(OVX) rat. These protocols have been success-
fully tested against a high-potency reference
estrogen-receptor agonist, 17α-ethinyl estra-
diol (EE), and a reference estrogen-receptor
antagonist, ZM 189,154. All protocols were
robust, reproducible, and transferable across
laboratories using these reference compounds
(Kanno et al. 2001). Therefore, the VMG
proceeded with the design and execution
of phase 2 of the uterotrophic bioassay’s
validation program.
A key objective of validation exercises is
to demonstrate the reliability of the standard-
ized protocols. Reliability includes a demon-
stration of the transferability of the protocols
among laboratories and the reproducibility of
the results from those protocols among labo-
ratories. Such a demonstration is expected to
employ test substances that represent the sub-
stances of likely concern in regulatory use, for
example, in the case of the uterotrophic
bioassay, weak estrogen-receptor agonists.
This article compares the reproducibility of
the dose responses of ﬁve weak estrogen ago-
nists using four protocols that include both
oral gavage and subcutaneous (sc) routes of
administration. An accompanying article
demonstrates the reproducibility of the
uterotrophic bioassay with prescribed doses
selected from this study with blind or coded
samples of all five weak agonists, two pre-
scribed EE doses, and a negative test
substance (Kanno et al. 2003).
Materials and Methods
Test substances and animals. A centralized
chemical repository at TNO, Zeist, the
Netherlands, received donated or purchased
test substances, weighed and prepared
appropriate aliquots in vials for shipment,
provided speciﬁc instructions for dilution of
each substance to prearranged dosages, and
arranged the shipment of test substances to
the participating laboratories. The test sub-
stance sources were Kraemer & Martin
(Krefeld, Germany) for EE (CAS no. 57-63-6;
purity min. 99%); Bayer AG (Wuppertal,
Germany) for bisphenol A (BPA; CAS no. 80-
05-7; purity 99.9%); ChemCon GmbH
(Freiburg, Germany) for genistein (GN; CAS
no. 446-72-0, purity min. 98%; chemically
synthesized); Sigma-Aldrich (St. Louis, MO,
USA) for methoxychlor (MX; CAS no. 72-
43-5; purity 95%); Schenectady International
Inc. (Schenectady, NY, USA) for a branched-
chain isomers mixture of nonylphenol (NP;
CAS no. 25154-52-3, lot 14081-001; purity
95.6%); and Promochem GmbH (Wesel,
Germany) for 1,1,1-trichloro-2,2-bis(o,p´-
chlorophenyl)ethane (o,p´-DDT; CAS no.
789-02-6, purity 99.8%). Separate vials of test
substance were supplied for the dose–response
study and the parallel coded, single-dose
study. The laboratories weighed out the
required test substance amounts to make up
the necessary test solutions in accordance with
prepared instructions using their normal stan-
dard operating procedures. The instructions
were provided to ensure that the doses were
comparable across the laboratories for the sta-
tistical analyses.
Participating laboratories obtained
animals from their normal external or inter-
nal sources, including the strain and the ani-
mal supply source for the program records.
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The Organisation for Economic Co-operation and Development has completed phase 2 of an
international validation program for the rodent uterotrophic bioassay. The purpose of the valida-
tion program was to demonstrate the performance of two versions of the uterotrophic bioassay,
the immature female rat and the adult ovariectomized rat, in four standardized protocols. This
article reports the dose–response studies of the validation program; the coded single-dose studies
are reported in an accompanying paper. The dose–response study design used ﬁve selected weak
estrogen agonists, bisphenol A, genistein, methoxychlor, nonylphenol, and o,p´-DDT. These weak
agonists were administered in a prescribed series of doses to measure the performance and repro-
ducibility of the protocols among the participating laboratories. All protocols successfully detected
increases in uterine weights when the weak agonists were administered. Within each protocol,
there was good agreement and reproducibility of the dose response among laboratories with each
substance. Substance-speciﬁc variations were observed in the inﬂuence of the route of administra-
tion on the uterine response, the potency as related to the dose producing the ﬁrst statistically sig-
nificant increase in uterine weights, and the maximum increase in uterine weight. Substantive
performance differences were not observed between the uterotrophic bioassay versions or among
the standardized protocols, and these were judged to be qualitatively equivalent. It is noteworthy
that these results were reproducible under a variety of different experimental conditions (e.g., ani-
mal strain, diet, housing, bedding, vehicle, animal age), indicating that the bioassay’s performance
as a screen is robust. In conclusion, both the intact, immature, and adult OVX versions, and all
protocols appear to be reproducible and transferable across laboratories and are able to detect
weak estrogen agonists. Key words: endocrine disruption, estrogen, rat uterus, uterotrophic.
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accordance with the OECD’s guidelines on
animal care (OECD 2000) and appropriate
national regulations. Animal housing temper-
ature was 22 ± 3C°, the relative humidity was
between 30 and 70%, and lighting cycle was
12 hr light and 12 hr dark. If bedding was
used, the type and supplier were recorded.
Immature animals were group housed with
two or three animals per cage, and housing
practices for OVX animals were from one to
two animals per cage. Feed and tap or ﬁltered
drinking water were provided ad libitum. The
rats were fed the usual rodent diet of the par-
ticipating laboratory, and the particular diet,
the supplier, and the batch or lot number(s)
of the diet were recorded. Laboratories did
not change the diet during the validation pro-
gram, and a sample of each lot was frozen and
retained for phytoestrogen analyses. In those
cases where multiple lots of diet may have
been used in a laboratory, the same lot of diet
was used for a given protocol. The dietary
analyses and the relation of phytoestrogen lev-
els to the uterotrophic bioassay’s performance
are reported separately (Owens et al. 2003).
Immature, intact animals. Immature
animals, if externally supplied, were received
either with dams or foster dams on approxi-
mately postnatal day (pnd) 14 (date of birth
= pnd 0) or as weanlings on pnd 17. Animals
were examined for overt signs of ill health and
anomalies, and healthy animals were reaccli-
matized. Animals were allocated into treat-
ment groups of six animals by randomization,
ensuring that all groups of animals had a
mean weight within ± 5% probability level.
Test substance administration could begin at
the choice of the participating laboratory on
pnd 18, 19, or 20.
Ovariectomized animals. At the time of
ovariectomy, the animals were between 42
and 56 days of age. The dorsolateral abdomi-
nal wall was opened at the midpoint between
the costal inferior border and the iliac crest
and a few millimeters lateral to the lateral
margin of the lumbar muscle. The ovaries
were located, removed from the abdominal
cavity, and detached by incision at the junc-
tion of the oviduct and each uterine horn.
After conﬁrming that no signiﬁcant bleeding
occurred, the abdominal wall was closed by
suture, and the skin was closed, for example,
by autoclips. The animals were allowed to
recover and the uterus weight was allowed to
regress for a minimum of 14 days before use.
Protocols. The individual protocols have
been described previously (Kanno et al.
2001). Brieﬂy, protocol A used intact, imma-
ture female rats as described above with dos-
ing by oral gavage for 3 consecutive days.
Protocol B used intact, immature female rats
with dosing by sc injection for 3 consecutive
days. Protocol C used young adult OVX rats
as described above with dosing by sc injection
for 3 consecutive days. Protocol D [previously
called “protocol C” (Kanno et al. 2001)] also
used young adult OVX rats and extended the
sc injection dosing to a total of 7 days. As
with phase 1, for demonstrating the basic tox-
icologic attribute of differences in chemical
potency due to the route of administration,
the VMG decided that only the immature
version and the satellite study were adequate
to conserve animals and resources. In all pro-
tocols, animals were humanely sacrificed
24 hr after the last dose administration.
Vehicle, test substance preparation, and
dosing. Test substances were dissolved in a
minimal amount of 95% ethanol and diluted
to final working concentration in the test
vehicle typically used by the participating lab-
oratory (e.g., corn, arachis, sesame, or olive
oil). If necessary, the test substance was dis-
solved with the assistance of gentle heating
and vigorous mechanical assistance, for exam-
ple, homogenized for several minutes in a
rotor-stator homogenizer. As the literature
indicated, the substances were stable, and
most laboratories prepared the test substance
weekly. The participating laboratories
recorded the nature of the vehicle, the sup-
plier, and lot number, and a sample of the
vehicle was retained for analysis, if that
became necessary.
Test substance administration was once
per day for 3 consecutive days in three proto-
cols (A, B, and C), and once per day for 7
consecutive days in a fourth protocol (D).
The amount administered was calculated
using the body weight (bw) of the animal
recorded on the day of treatment. Treatment
on each consecutive day was at approximately
the same time and sequence for each animal.
For oral gavage (protocol A and a single satel-
lite study using oral gavage with OVX ani-
mals for 3 days), the total volume per rat per
day did not exceed 5 mL/kg bw/day. For sc
injection (protocols B, C, and D), the total
amount of sc injection per rat per day did not
exceed 4 mL/kg bw/day, and the maximum
volume per injection site per rat did not
exceed 0.2 mL. The precise method and vol-
umes of administration by the individual par-
ticipating laboratory were recorded. Animals
were observed for clinical signs, the body
weights were recorded daily to 0.1 g, any ani-
mals observed to be in distress were humanely
sacrificed, and any animals found dead were
disposed of.
Necropsy, dissection, and uterine weight.
Twenty-four hours after the last treatment,
the animals were humanely killed by the
method routinely used by the participating
laboratory in the same sequence as the test
substance was administered. The uterus was
carefully dissected, the ovaries of immature
animals removed, and the uterus trimmed of
fascia and fat to avoid loss of luminal
contents. The uterus and cervix were removed
by incision at the vaginal fornix to preserve
the luminal fluid contents. The uterus was
transferred to a marked, tared container with
care to avoid desiccation. This first uterine
weight (wet weight) included the luminal
ﬂuid contents and was recorded to the nearest
0.1 mg. Each uterus was then opened by
piercing or longitudinal cuts into the uterine
wall, and the luminal ﬂuid was expressed with
gentle pressure on moistened ﬁlter paper. The
uterus was then weighed a second time (blot-
ted weight), and the weight was recorded to
the nearest 0.1 mg.
Study management and quality control.
The study director was on the OECD staff,
and each laboratory nominated a principal
investigator as recommended by OECD
Good Laboratory Practice and Study
Management guidelines (OECD 2002). The
laboratories were requested to perform these
studies under these OECD Good Laboratory
Practice guidelines and most, but not all, did
so. When data were assembled and an initial
statistical analysis performed, all laboratories
were requested to audit these raw data and to
respond to specific queries on outliers and
questionable data. A small number of data
corrections were made, and reporting errors
on dilutions, samples, and identity of control
groups were either corrected or clariﬁed.
Statistics. The raw data uterine weights
and body weights from each participating lab-
oratory were recorded on a standardized elec-
tronic spreadsheet and submitted to an
independent statistician for analysis. The
uterine data were evaluated by an analysis of
covariance approach with body weight at
necropsy as the covariable. A variance-stabiliz-
ing logarithmic transformation was carried
out on the uterine data prior to the data
analysis. The Dunnett and Hsu test was used
for making pairwise comparisons of each
dosed group to vehicle controls and to calcu-
late the confidence intervals. Studentized
residual plots were used to detect possible
outliers and to assess homogeneity of vari-
ances. The data were analyzed using the
PROC GLM in the Statistical Analysis
System (version 8; SAS Institute, Cary, NC).
In addition to the ratio of the mean uterine
weights (the treated groups relative to the
vehicle control groups) in Tables 2–26, the
ratio of the geometric means of the uterine
weights (treated relative to the vehicle con-
trol) after adjusting for the body weight of the
animal at necropsy was also calculated.
Design of Phase 2
Dose–Response Study
The principal question was whether the
standardized protocols would achieve the
same degree of reliability and reproducibility,
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when testing selected substances of lower
estrogenic potencies. The primary objectives
of the phase 2 dose–response studies were to
demonstrate that participating laboratories
could detect several selected weak estrogen
agonists by a statistically significant increase
in uterine weights, that the results were repro-
ducible across laboratories, and that the ani-
mals would respond in a dose-related manner.
The doses producing the first significant
increase in uterine weights and the magnitude
of the responses of these weak agonists were
also to be compared with the potent reference
estrogen, EE. Other objectives were to test
whether the intact, immature version and the
OVX version were generally equivalent in
performance and their ability to detect the
activity of weak agonists, and to quantify the
variability of the dose response among labora-
tories and among protocols testing the equiv-
alence of the protocols. The statistical analyses
of these performance comparisons and deter-
minations required a series of identical, pre-
scribed doses for each test substance. If any
laboratory was unable to detect the selected
weak agonists, an effort would be made to
determine the responsible factors.
Selection of Weak Agonists
and Doses
The VMG selected five weak estrogen
agonists: BPA, GN, MX, NP, and o,p´-DDT.
For these substances, a) individual binding
affinities to the estrogen receptor had been
determined in a single laboratory, b) evidence
from the literature was available for estrogen-
mediated activity in other in vitro assay sys-
tems, c) evidence from the literature was
available that each weak agonist displayed
positive response in the uterotrophic bioassay,
and d) either subchronic or chronic testing
data were available to indicate whether the
compounds elicited estrogen-related effects,
or such subchronic or chronic testing was in
progress. Collectively, such data indicated
that the selected substances were weak estro-
gen receptor agonists in vitro, were positive
challenge substances for a validation study of
the uterotrophic bioassay, and there were suf-
ficient data for estrogen-related effects in
higher tiers to assess the predictivity of the
uterotrophic bioassay at the end of the valida-
tion program. These data are compliant with
test substance selection recommendations to
demonstrate the characteristics of a bioassay
for validation studies and the relationship of a
bioassay to other assays in a hierarchical,
tiered approach (ICCVAM 1997; OECD
1998b). The chemical identities and estrogen-
receptor binding data from Blair et al. (2000)
and Branham et al. (2002) are shown in
Table 1. The binding afﬁnities of the selected
weak agonists relative to 17β-estradiol cover a
range of almost three orders of magnitude, for
example, log –0.35 to –3.20, and even the
two most potent selected agonists, GN and
the metabolite of MX, are almost three orders
of magnitude weaker than the reference EE
agonist. Therefore, the selected weak agonists
were judged to represent the range of potency
that the uterotrophic bioassay would likely
encounter in regulatory applications.
In addition, test substances were selected
for expected differences in behavior in phar-
macokinetic behavior to represent the variety
of test substances likely to be encountered by
the uterotrophic bioassay during use and to
demonstrate differences between the oral and
sc routes of administration observed in several
pharmacokinetic studies below. Three test
substances—BPA, GN, and NP—are
reported to be rapidly eliminated and to
undergo significant intestinal and hepatic
conjugation, leading to a hypothesis of lower
potency by the oral route of administration
(Chang et al. 2000; Coldham and Sauer
2000; Fennell et al. 1998; Miyakoda et al.
2000; Müller et al. 1998; Pottenger et al.
2000). MX is reported to undergo hepatic
activation, leading to a hypothesis of higher
potency by the oral route of administration
(Bulger et al. 1978). Finally, o,p´-DDT was
selected because of the absence of a hydroxyl
group necessary for rapid conjugation, and its
persistence and bioaccumulation, leading to
the hypothesis that it might display unique
pharmacokinetic characteristics. Therefore,
the selected weak agonists were judged to rep-
resent the range of test substance characteris-
tics that the uterotrophic bioassay would
likely encounter in regulatory applications.
As part of the overall design, five doses
were recommended for each test substance.
However, because of possible resource con-
straints, participating laboratories were
required to use only the three intermediate
doses. The VMG established a working group
to review the scientific literature concerning
each of the test substances, to consult
researches for unpublished data, and then to
select the doses for each substance and route
of administration. Unfortunately, much of
the background literature information from
both published and “gray” sources did not
report all necessary protocol details, use
deﬁned and closely interspersed doses, or con-
sistently report the data as absolute uterine
weight increases. Thus, the literature studies
were not strictly comparable or unambiguous
for dose-selection purposes. Because of the
urgency and the complex logistics of an inter-
national validation program, the VMG
decided to forego preliminary dose-setting
studies. Therefore, the working group was
required to rely upon its own expert judg-
ment to recommend the dose levels, and risks
were accepted that some laboratories might
not achieve a complete dose–response curve.
To conserve animals and resources and to
achieve a core of robust data for comparison,
the VMG decided that priority in the
dose–response work was to compare the
results for NP and BPA. If additional labora-
tory resources were available, the remaining
weak agonists, GN, MX and o,p´-DDT,
would be examined. The doses recommended
for the oral gavage studies were as follows: for
BPA—60, 200, 375, 600, and 1,000
mg/kg/day; for GN—20, 60, 120, 300, and
500 mg/kg/day; for MX—20, 50, 120, 300,
and 500 mg/kg/day; for NP—15, 75, 125,
250, and 350 mg/kg/day; and for o,p´-
DDT—10, 50, 125, 300, and 600
mg/kg/day. The doses recommended for the
sc injection studies were as follows: for
BPA—10, 100, 300, 600, and 800
mg/kg/day; for GN—1, 15, 35, 50, and 80
mg/kg/day; for MX—20, 100, 250, 500, and
800 mg/kg/day; for NP—5, 15, 35, 80, and
100 mg/kg/day; and for o,p´-DDT—5, 25,
50, 100, and 200 mg/kg/day. All of the above
doses were lower than the standard toxico-
logic limit dose of 1,000 mg/kg/day except
for the ﬁnal oral gavage dose of BPA, which
was at the limit dose.
Results of Phase 2
Dose–Response Studies
A total of 86 dose–response studies were per-
formed by 17 laboratories. Four other labora-
tories, which either participated in phase 1
(Kanno et al. 2001) or the coded single-dose
studies in phase 2 (Kanno et al. 2003), did
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Table 1. Rat uterine cytosol ERα receptor–binding data.a,b
Chemical name Mean IC50 (M) ± SEM RBA (%) Log RBA
EE 4.73 × 10–10 ±0 . 60 × 10–10 190.063 2.28
17β-Estradiol 8.99 × 10–10 ±0 . 27 × 10–10 100.000 2.00
GN 2.00 × 10–7 ±0 . 21 × 10–7 0.443 –0.35
HPTE 3.55 × 10–7 ±0 . 15 × 10–7 0.253 –0.60
NP 3.05 × 10–6 ±0 . 15 × 10–6 0.029 –1.53
BPA 1.17 × 10–5 ±0 . 64 × 10–5  0.008 –2.11
o,p´-DDT 6.43  × 10–5 ±0 . 89 × 10–5 0.001 –2.85
MX 1.44 × 10–4 ±0 . 66 × 10–4 0.001 –3.20
Abbreviations: IC50, the concentration of ligand that reduces the binding of native 17β-estradiol by 50%; RBA, relative
binding afﬁnity of the ligand to the native 17β-estradiol.
aData modiﬁed from tables in Blair et al. (2000) and Branham et al. (2002).bThe binding curves were generated in a single
laboratory on the basis of a single protocol using closely interspersed concentrations and performed in triplicate.not participate in the dose–response studies.
Because the laboratory numbers were kept
consistent from 1 through 21 throughout the
entire program, laboratories numbers 10, 16,
17, and 19 will not appear in this paper. 
Mortalities, decreases in body weight or
body weight gain, and clinical signs. Out of a
total of 2,652 animals, there were 45 mortali-
ties observed in 10 laboratories: 5 in BPA
studies, 6 in MC studies, 19 in NP studies,
and 15 in DDT studies. Forty-two of the
mortalities were in protocol A treatment stud-
ies using oral gavage. A dose-related pattern of
modest reductions in body weights and
diminished body weight gains was often
observed in the immature animal studies and
in the extending dosing of the OVX studies.
Decreases in body weights at terminal sacri-
fice approaching or greater than 10%, indi-
cating that the dose exceeded a maximum
tolerated dose, were observed at doses of
100 mg BPA/kg/day and higher in both pro-
tocol D studies, at doses of 500 mg
MX/kg/day and higher in both protocol D
studies, at doses of 75 mg NP/kg/day and
higher in 3 of 4 protocol A studies, and at
doses of 300 mg DDT/kg/day in all protocol
A studies. Clinical signs were reported in con-
junction with the mortalities and body weight
losses, including piloerection, lethargy and
reduced mobility, and labored breathing.
Bisphenol A. A total of 22 dose–response
studies were conducted with BPA, including
4 with protocol A, 10 with protocol B, 5 with
protocol C, 2 with protocol D, and a satellite
study using oral gavage with OVX animals.
Twenty of 21 studies were successful in
detecting increases in uterine weights at one
or more of the prescribed doses. In the case of
laboratory 21, the required terminal body
weights were not recorded for the
dose–response studies. Because the statistical
analysis was based upon using terminal body
weights as a covariant with the uterine blotted
weight data, the body weight–adjusted statis-
tical analysis was not performed on the data
from this laboratory. However, the data such
as mean wet and blotted uterine weights for
laboratory 21 are reported in Table 3 and
Figure 1, and these have been statistically
compared without body weight adjustment.
Within each protocol, there was overall
agreement among different laboratories both
in the magnitude of the uterine weight
increases and in the BPA doses ﬁrst producing
a statistically significant increase in uterine
weight. In protocol A using oral gavage, all
four studies detected statistically significant
increases in uterine weights at lowest observed
effect level (LOEL) doses of 375 mg
BPA/kg/day (two studies), 600 mg/kg/day
(one study), and 1,000 mg/kg/day (one
study) (Table 2). In protocol B, eight studies
detected statistically significant increases in
uterine weights at doses of 10 mg
BPA/kg/day (one study), 100 mg/kg/day
(three studies), 300 mg/kg/day (three studies),
and 600 mg/kg/day (one study). However, in
a ninth study, statistical significance was
achieved at doses of 10 and 100 mg
BPA/kg/day, no statistical difference was
observed at 300 mg/kg/day, and statistically
significant decreases in uterine weights were
observed at 600 and 800 mg BPA/kg/day.
Effectively, the reported dose response in this
laboratory was the mirror opposite of the
expectations and the results from all other
laboratories (Table 3, laboratory 20). In pro-
tocol C, all ﬁve of the studies detected statisti-
cal significance at doses of 100 mg
BPA/kg/day (Table 4). In protocol D, both
studies detected statistical signiﬁcance at doses
of 100 mg BPA/kg/day (Table 5). The satel-
lite study with OVX animals using oral gav-
age administration did not detect statistically
significant increases in uterine weight at the
highest of the three intermediate doses used
in that study, 600 mg/kg/day (i.e., the highest
1,000-mg BPA/kg/day dose was not tested in
this laboratory with this protocol) (Table 6).
The BPA results, except for the satellite
study, are shown graphically in Figure 1. In
protocols B, C, and D using sc injection, the
ratio of the maximum mean uterine weights
of the treated groups relative to the vehicle
controls was generally between 3 and 4. The
slope appeared to be steeper in the OVX ani-
mals, and the extension of the dosing to 7
days appeared to slightly increase the overall
response. The maximum increase observed in
uterine weights was considerably lower in
protocol A, where the ratio of the maximum
uterine weight increase to the vehicle controls
was approximately 1.5 relative to the controls,
and there was greater variability among the
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Table 2. Uterine weights, body weights, and ratio of the relative increase in uterine weights for bisphenol A in protocol A.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (60 mg/kg/day) (200 mg/kg/day) (375 mg/kg/day) (600 mg/kg/day) (1,000 mg/kg/day)
2 Wet weight (mg, mean ± SD) 26.5 ± 4.20 26.8 ± 3.23 30.1 ± 1.60 30.4 ± 5.82 37.0 ± 5.54 44.1 ± 8.36a
Blotted weight (mg, mean ± SD) 25.4 ± 4.19 25.7 ± 2.94 29.0 ± 1.86 29.4 ± 5.85 35.8 ± 5.68 42.8 ± 8.32
bw (g, mean ± SD) 46.6 ± 7.14 48.0 ± 5.86 47.7 ± 3.48 42.5 ± 4.59 44.3 ± 4.00 45.3 ± 3.35
Absolute ratiob 1.01 1.14 1.16 1.41 1.69
bw adjusted ratioc 0.99 1.13 1.26* 1.49* 1.73*
(Lower CL, upper CL)d (0.83, 1.17) (0.95, 1.34) (1.06, 1.50) (1.25, 1.77) (1.45, 2.07)
7 Wet weight (mg, mean ± SD) 30.9 ± 2.95 33.1 ± 3.24 36.0 ± 3.46 37.5 ± 4.35 50.9 ± 18.34 52.0 ± 3.19
Blotted weight (mg, mean ± SD) 29.5 ± 2.95 32.2 ± 3.13 34.8 ± 3.48 36.1 ± 3.89 49.1 ± 17.77 50.4 ± 2.94
bw (g, mean ± SD) 56.7 ± 1.74 56.3 ± 3.51 55.0 ± 3.15 54.8 ± 2.75 53.5 ± 3.92 53.5 ± 2.29
Absolute ratio  0.89 0.96 1.00 1.36 1.40
bw adjusted ratio 0.89 0.97 1.00 1.31* 1.40*
(Lower CL, upper CL) (0.70, 1.13) (0.76, 1.22) (0.79, 1.27) (1.03, 1.66) (1.10, 1.78)
12 Wet weight (mg, mean ± SD) 24.2 ± 2.48 Not done 29.6 ± 5.75 31.0 ± 1.43 39.1 ± 7.43e Not done
Blotted weight (mg, mean ± SD) 20.6 ± 1.81 25.8 ± 5.19 26.8 ± 2.44 33.8 ± 6.04
bw (g, mean ± SD) 39.7 ± 3.10 38.5 ± 2.17 33.7 ± 3.82 39.5 ± 6.00
Absolute ratio  1.26 1.30 1.64
bw adjusted ratio 1.25 1.36* 1.63*
(Lower CL, upper CL) (0.9995f, 1.56) (1.05, 1.76) (1.29, 2.06)
13 Wet weight (mg, mean ± SD) 39.0 ± 6.51 39.7 ± 4.93 49.7 ± 20.39 43.3 ± 5.35 43.0 ± 4.30c 59.0 ± 9.27
Blotted weight (mg, mean ± SD) 31.8 ± 3.66 32.0 ± 3.35 32.6 ± 14.60 32.3 ± 3.98 34.4 ± 2.70 49.0 ± 8.72
Body weight (g, mean ± SD) 41.5 ± 2.74 42.2 ± 3.66 42.3 ± 19.70 39.5 ± 3.78 31.4 ± 3.36 38.0 ± 3.58
Absolute ratio  1.01 1.02 1.02 1.08 1.54
bw adjusted ratio 1.00 1.16 1.03 1.17 1.57*
(Lower CL, upper CL) (0.77, 1.31) (0.88, 1.51) (0.78, 1.35) (0.79, 1.72) (1.18, 2.08)
aOne animal died in 1,000-mg BPA/kg/day group before necropsy. bRatio of arithmetic means of the treated blotted uterine weights relative to the vehicle control blotted uterine weights.
cRatio of geometric means of treated blotted uterine weights relative to the vehicle control blotted uterine weights after adjusting for the body weights at necropsy as a covariable.
dLower and upper 95% conﬁdence limits (CL) for ratio of blotted uterine weights based on body weights as a covariable. eOne animal died in 600 mg BPA/kg/day group before necropsy.
fWith the lower 95% conﬁdence limit not > 1.0, the result is not statistically signiﬁcant. *Level of signiﬁcance, p < 0.05.studies. Comparing protocols B and C,
the dose–response curves among laboratories
are somewhat more variable between the
intact, immature animals and the OVX ani-
mals are not appreciably different, taking into
consideration the larger number of laborato-
ries conducting protocol B (Figure 1).
Genistein. A total of 14 dose–response
studies were conducted with GN, including 4
with protocol A, 4 with protocol B, 3 with
protocol C, 2 with protocol D, and a satellite
study using oral gavage with OVX animals.
All studies in all protocols were successful in
detecting increases in uterine weights at one
or more prescribed doses.
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Table 3. Uterine weights, body weights, and ratio of the relative increase in uterine weights for bisphenol A in protocol B.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (10 mg/kg/day) (100 mg/kg/day) (300 mg/kg/day) (600 mg/kg/day) (800 mg/kg/day)
2 Wet weight (mg, mean ± SD) 28.1 ± 1.98 31.0 ± 2.42 46.2 ± 6.92 62.1 ± 6.24 98.3 ± 27.58 144.5 ± 53.95
Blotted weight (mg, mean ± SD) 26.5 ± 1.80 29.4 ± 2.44 44.5 ± 6.40 59.8 ± 5.72 88.0 ± 17.01 105.0 ± 15.13
bw (g, mean ± SD) 51.5 ± 2.45 49.9 ± 2.88 51.5 ± 3.56 48.8 ± 3.53 50.5 ± 2.23 49.5 ± 3.85
Absolute ratio  1.11 1.68 2.25 3.32 3.96
bw adjusted ratio 1.12 1.67* 2.30* 3.30* 4.00*
(Lower CL, upper CL)a (0.92, 1.36) (1.37, 2.02) (1.88, 2.81) (2.72, 4.01) (3.28, 4.87)
6 Wet weight (mg, mean ± SD) 61.1 ± 15.24 Not done 72.7 ± 17.73 80.6 ± 16.86 131.7 ± 59.15b Not done
Blotted weight (mg, mean ± SD) 58.0 ± 14.00 69.1 ± 17.38 76.8 ± 15.96 115.5 ± 39.04
bw (g, mean ± SD) 48.9 ± 8.15 49.0 ± 6.92 47.9 ± 7.07 52.6 ± 6.68
Absolute ratio  1.19 1.32 1.99
bw adjusted ratio 1.18 1.37* 1.75*
(Lower CL, upper CL) (0.90, 1.54) (1.05, 1.79) (1.31, 2.33)
7 Wet weight (mg, mean ± SD) 34.5 ± 4.30 34.0 ± 2.82 44.2 ± 4.32 65.9 ± 10.58 161.6 ± 38.51 209.7 ± 35.88
Blotted weight (mg, mean ± SD) 32.8 ± 4.26 32.9 ± 2.92 42.8 ± 4.22 64.2 ± 9.88 113.0 ± 10.39 119.0 ± 9.64
bw (g, mean ± SD) 57.6 ± 4.26 56.6 ± 3.96 57.2 ± 3.70 57.2 ± 3.57 54.9 ± 2.67 54.7 ± 2.69
Absolute ratio  1.00 1.30 1.95 3.44 3.63
bw adjusted ratio 1.01 1.31* 1.95* 3.47* 3.66*
(Lower CL, upper CL) (0.85, 1.20) (1.10, 1.56) (1.64, 2.32) (2.90, 4.15) (3.06, 4.37)
8 Wet weight (mg, mean ± SD) 25.2 ± 2.79 29.5 ± 4.42 36.5 ± 5.35 48.1 ± 7.34 53.4 ± 11.59 77.4 ± 16.85
Blotted weight (mg, mean ± SD) 23.5 ± 2.33 27.8 ± 4.24 34.5 ± 5.07 45.5 ± 7.26 50.7 ± 10.71 70.1 ± 9.13
bw (g, mean ± SD) 51.9 ± 6.75 52.1 ± 7.57 50.8 ± 1.96 52.6 ± 3.59 51.4 ± 7.00 49.6 ± 5.42
Absolute ratio  1.18 1.47 1.93 2.15 2.98
bw adjusted ratio 1.17 1.47* 1.91* 2.13* 3.01*
(Lower CL, upper CL) (0.92, 1.50) (1.15, 1.87) (1.50, 2.43) (1.67, 2.71) (2.36, 3.84)
12 Wet weight (mg, mean ± SD) 26.8 ± 6.97 Not done 34.7 ± 3.59 32.1 ± 6.64 65.2 ± 23.00 Not done
Blotted weight (mg, mean ± SD) 22.4 ± 6.47 31.4 ± 4.47 28.2 ± 6.64 56.3 ± 17.81
bw (g, mean ± SD) 40.4 ± 3.38 38.1 ± 5.62 36.8 ± 5.79 39.7 ± 4.08
Absolute ratio  1.40 1.26 2.51
bw adjusted ratio 1.47 1.33 2.51*
(Lower CL, upper CL) (0.9925c, 2.19) (0.88, 1.99) (1.70, 3.70)
13 Wet weight (mg, mean ± SD) 33.4 ± 7.02 37.0 ± 9.27 45.3 ± 6.56 61.5 ± 10.82 112.7 ± 35.60 142.0 ± 25.64
Blotted weight (mg, mean ± SD) 28.0 ± 3.46 31.2 ± 7.28 38.8 ± 12.95 51.3 ± 15.60 82.2 ± 31.40 104.8 ± 8.80
bw (g, mean ± SD) 45.2 ± 2.32 44.2 ± 3.60 41.5 ± 4.04 45.8 ± 3.06 43.3 ± 3.56 42.3 ± 2.73
Absolute ratio  1.11 1.39 1.83 2.93 3.74
bw adjusted ratio 1.14 1.50 1.72* 2.88* 4.15*
(Lower CL, upper CL) (0.71, 1.82) (0.91, 2.47) (1.08, 2.76) (1.78, 4.64) (2.55, 6.77)
15 Wet weight (mg, mean ± SD) 33.2 ± 5.56 35.3 ± 8.19 36.2 ± 4.26 50.2 ± 6.18 82.8 ± 23.64 132.7 ± 43.37
Blotted weight (mg, mean ± SD) 28.7 ± 5.47 26.3 ± 4.68 27.3 ± 4.80 36.8 ± 6.91 67.8 ± 13.00 87.5 ± 18.07
bw (g, mean ± SD) 48.3 ± 3.65 46.3 ± 3.70 46.4 ± 2.38 44.8 ± 3.84 44.3 ± 4.77 46.9 ± 3.16
Absolute ratio  0.92 0.95 1.28 2.37 3.05
bw adjusted ratio 0.95 0.98 1.37* 2.54* 3.11*
(Lower CL, upper CL) (0.72, 1.25) (0.75, 1.29) (1.03, 1.81) (1.91, 3.37) (2.37, 4.08)
18 Wet weight (mg, mean ± SD) 25.0 ± 1.66 30.9 ± 3.00 37.7 ± 3.27 51.1 ± 5.50 98.6 ± 16.36 144.9 ± 44.28
Blotted weight (mg, mean ± SD) 21.3 ± 1.50 28.5 ± 3.62 33.8 ± 3.85 46.6 ± 5.28 72.1 ± 5.41 95.0 ± 10.63
bw (g, mean ± SD) 52.1 ± 3.70 57.1 ± 4.91 53.0 ± 4.55 55.1 ± 3.76 53.8 ± 3.11 52.6 ± 3.02
Absolute ratio  1.34 1.59 2.19 3.38 4.46
bw adjusted ratio 1.28* 1.57* 2.12* 3.33* 4.42*
(Lower CL, upper CL) (1.08, 1.51) (1.34, 1.83) (1.81, 2.50) (2.85, 3.91) (3.78, 5.17)
20 Wet weight (mg, mean ± SD) 57.7 ± 13.08 36.2 ± 7.20 35.8 ± 4.29 53.7 ± 9.83 90.2 ± 18.97 107.3 ± 30.72
Blotted weight (mg, mean ± SD) 54.3 ± 11.77 27.4 ± 7.56 31.6 ± 4.90 50.8 ± 9.08 81.7 ± 13.65 92.9 ± 15.35
bw (g, mean ± SD) 50.7 ± 4.01 51.6 ± 1.78 52.8 ± 1.74 51.4 ± 1.87 50.4 ± 3.32 51.4 ± 2.84
Absolute ratio  1.71 1.50 0.94 0.58 0.51
bw adjusted ratio 1.75* 1.57* 0.95 0.59 0.50
(Lower CL, upper CL) (1.26, 2.43) (1.12, 2.19) (0.69, 1.32) (0.42, 0.81) (0.36, 0.69)
21 Wet weight (mg, mean ± SD) 58.0 ± 7.84 81.4 ± 9.96 88.8 ± 8.72 107.7 ± 12.03 120.9 ± 15.32 136.1 ± 13.55
Blotted weight (mg, mean ± SD) 47.3 ± 6.92 67.7 ± 7.79 71.0 ± 9.08 89.0 ± 11.37 93.4 ± 14.04 113.7 ± 10.19
bw (g, mean ± SD) —d —d —d —d —d —d
Absolute ratio  1.43*e 1.50*e 1.89*e 1.97*e 2.42*e
bw adjusted ratio —d —d —d —d —d
(Lower CL, upper CL) —d —d —d —d —d
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. bOne animal died in 600 mg BPA/kg/day group before necropsy.
cWith the lower 95% conﬁdence limit not > 1.0, the result is not statistically signiﬁcant. dTerminal body weights were not recorded by the laboratory. eThe blotted uterine weights were
analyzed without body weight adjustments and were found to be statistically signiﬁcant. *Level of signiﬁcance, p < 0.05.Within each protocol, there was overall
agreement among different laboratories both in
the magnitude of the uterine weight increases
and in the GN doses ﬁrst producing a statisti-
cally signiﬁcant increase in uterine weight. In
protocol A using oral gavage, two studies
detected statistically significant increases in
uterine weights at LOEL doses of 20 mg
GN/kg/day and the other two studies at doses
of 60 mg/kg/day (Table 7). In protocol B, one
study detected statistically signiﬁcant increases
in uterine weights at a dose of 1 mg GN/kg/day
and the other three studies at doses of 15
mg/kg/day (Table 8). In protocol C, two of the
studies detected statistical signiﬁcance at doses
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Table 4. Uterine weights, body weights, and ratio of the relative increase in uterine weights for bisphenol A in protocol C.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (10 mg/kg/day) (100 mg/kg/day) (300 mg/kg/day) (600 mg/kg/day) (800 mg/kg/day)
2 Wet weight (mg, mean ± SD) 103.9 ± 13.20 116.9 ± 13.00 210.3 ± 62.72 439.1 ± 129.16 588.4 ± 161.90 728.3 ± 201.57
Blotted weight (mg, mean ± SD) 99.8 ± 10.76 112.5 ± 11.69 188.3 ± 25.51 278.6 ± 35.86 306.7 ± 32.98 301.9 ± 43.25
bw (g, mean ± SD) 250.9 ± 13.24 251.4 ± 9.97 240.2 ± 12.08 238.0 ± 13.90 236.4 ± 11.03 229.9 ± 17.53
Absolute ratio  1.13 1.89 2.79 3.07 3.02
bw adjusted ratio 1.13 1.89* 2.79* 3.08* 3.03*
(Lower CL, upper CL)a (0.93, 1.37) (1.55, 2.30) (2.28, 3.41) (2.52, 3.78) (2.45, 3.75)
6 Wet weight (mg, mean ± SD) 115.5 ± 19.84 Not done 236.7 ± 43.08 274.1 ± 69.59 728.8 ± 207.15 Not done
Blotted weight (mg, mean ± SD) 110.7 ± 19.60 219.5 ± 45.59 236.1 ± 53.39 393.7 ± 68.46
bw (g, mean ± SD) 299.6 ± 29.76 291.6 ± 12.58 269.6 ± 24.97 277.5 ± 8.91
Absolute ratio  1.98 2.13 3.56
bw adjusted ratio 2.05* 2.41* 3.92*
(Lower CL, upper CL) (1.58, 2.66) (1.79, 3.23) (2.97, 5.18)
7 Wet weight (mg, mean ± SD) 91.4 ± 13.17 93.9 ± 10.84 150.3 ± 24.55 619.1 ± 157.48b 764.9 ± 173.18 825.8 ± 240.53
Blotted weight (mg, mean ± SD) 88.8 ± 12.90 91.5 ± 10.46 146.7 ± 23.53 294.2 ± 23.44 333.3 ± 32.99 318.5 ± 32.10
bw (g, mean ± SD) 250.2 ± 12.36 250.6 ± 13.27 243.3 ± 12.50 229.5 ± 11.72 236.5 ± 9.30 237.9 ± 9.74
Absolute ratio  1.03 1.65 3.31 3.75 3.59
bw adjusted ratio 1.03 1.67* 3.44* 3.85* 3.67*
(Lower CL, upper CL) (0.86, 1.24) (1.38, 2.01) (2.76, 4.30) (3.16, 4.70) (3.02, 4.47)
8 Wet weight (mg, mean ± SD) 92.5 ± 10.51 90.4 ± 7.82 152.1 ± 29.28 353.9 ± 86.49 355.3 ± 97.07 388.1 ± 113.91
Blotted weight (mg, mean ± SD) 88.0 ± 9.76 86.0 ± 7.29 139.3 ± 21.94 229.2 ± 35.16 243.4 ± 30.12 239.6 ± 35.55
bw (g, mean ± SD) 291.0 ± 17.09 291.5 ± 17.04 282.3 ± 11.60 281.2 ± 14.29 276.3 ± 21.93 276.5 ± 19.53
Absolute ratio  0.98 1.58 2.60 2.77 2.72
bw adjusted ratio 0.98 1.60* 2.65* 2.85* 2.79*
(Lower CL, upper CL) (0.80, 1.20) (1.31, 1.96) (2.16, 3.24) (2.32, 3.51) (2.27, 3.43)
12 Wet weight (mg, mean ± SD) 106.0 ± 18.84 Not done 225.4 ± 45.83 444.5 ± 89.56 837.0 ± 207.10 Not done
Blotted weight (mg, mean ± SD) 98.6 ± 22.04 197.4 ± 33.88 266.3 ± 44.60 314.1 ± 60.01
bw (g, mean ± SD) 297.2 ± 14.54 291.8 ± 12.26 299.9 ± 10.99 289.3 ± 23.00
Absolute ratio  2.00 2.70 3.19
bw adjusted ratio 2.03* 2.72* 3.24*
(Lower CL, upper CL) (1.53, 2.70) (2.05, 3.61) (2.43, 4.32)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. bOne animal died in 300 mg BPA/kg/day group before necropsy.
*Level of signiﬁcance, p < 0.05.
Table 5. Uterine weights, body weights, and ratio of the relative increase in uterine weights for bisphenol A in protocol D.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (10 mg/kg/day) (100 mg/kg/day) (300 mg/kg/day) (600 mg/kg/day) (800 mg/kg/day)
2 Wet weight (mg, mean ± SD) 89.0 ± 13.97 100.8 ± 16.54 214.5 ± 14.44 342.8 ± 42.58 613.0 ± 141.93 484.8 ± 139.04
Blotted weight (mg, mean ± SD) 86.2 ± 13.56 97.6 ± 16.07 209.7 ± 13.14 306.8 ± 18.43 389.9 ± 57.69 353.9 ± 48.07
bw (g, mean ± SD) 274.6 ± 15.93 269.2 ± 20.29 246.8 ±9.88 236.2 ± 10.71 242.5 ± 16.54 230.5 ± 24.79
Absolute ratio  1.13 2.43 3.56 4.52 4.11
bw adjusted ratio 1.14 2.53* 3.74* 4.69* 4.31*
(Lower CL, upper CL)a (0.91, 1.41) (1.99, 3.21) (2.89, 4.84) (3.67, 5.99) (3.28, 5.67)
7 Wet weight (mg, mean ± SD) 82.2 ± 2.94 91.1 ± 7.47 192.7 ± 6.30 358.8 ± 109.44 421.4 ± 72.68 525.8 ± 41.04
Blotted weight (mg, mean ± SD) 80.4 ± 2.70 88.8 ± 7.70 188.8 ± 4.96 314.1 ± 40.32 346.7 ± 41.94 376.9 ± 27.57
bw (g, mean ± SD) 283.7 ± 14.51 285.8 ± 14.66 259.1 ± 11.75 245.7 ± 5.74 249.5 ± 7.28 244.5 ± 6.29
Absolute ratio  1.11 2.35 3.91 4.32 4.69
bw adjusted ratio 1.10 2.35* 3.90* 4.30* 4.70*
(Lower CL, upper CL) (0.97, 1.26) (2.00, 2.77) (3.18, 4.78) (3.56, 5.19) (3.84, 5.75)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance, p < 0.05.
Table 6. Uterine weights, body weights, and ratio of the relative increase in uterine weights for bisphenol A in satellite OVX protocol by oral gavage.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (60 mg/kg/day) (200 mg/kg/day) (375 mg/kg/day) (600 mg/kg/day) (1,000 mg/kg/day)
12 Wet weight (mg, mean ± SD) 101.1 ± 16.93 Not done 120.9 ± 11.63 133.7 ± 38.71 130.9 ± 11.92 Not done
Blotted weight (mg, mean ± SD) 95.0 ± 16.43 112.4 ± 10.36 125.2 ± 38.35 125.3 ± 10.03
bw (g, mean ± SD) 295.5 ± 11.09 281.7 ±14.55 289.7 ± 11.37 278.5 ± 11.92
Absolute ratio  1.18 1.32 1.32
bw adjusted ratio 1.16 1.27 1.29
(Lower CL, upper CL)a (0.86, 1.56) (0.97, 1.68) (0.94, 1.75)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable.of 15 mg GN/kg/day and another at a dose of
35 mg/kg/day (Table 9). In protocol D, both
studies detected statistical signiﬁcance at doses
of 15 mg GN/kg/day (Table 10). The satellite
study with OVX animals using oral gavage
administration detected statistically signiﬁcant
increases in uterine weight at the lowest of the
three intermediate doses used in that study, 60
mg/kg/day (i.e., the lowest 20-mg GN/kg/day
dose was not tested in this laboratory with this
protocol) (Table 11).
The GN results, except for the satellite
study, are shown graphically in Figure 2. In
protocol A using oral gavage, the ratio of the
maximum mean uterine weights of the
treated groups to the controls was generally
between 2.5 and 3.5. In protocol B with
intact, immature animals, the ratio relative to
the controls was again 2.5 to nearly 4. In pro-
tocol C, the maximum induction was less,
with the ratio approaching 2. In protocol D
with extended dosing to 7 days, the response
in the mature OVX animals reached an
equivalent maximum response to the intact
immature animals after 3 days of dosing.
Methoxychlor. A total of 14 dose–response
studies were conducted with MX, including 4
with protocol A, 4 with protocol B, 3 with
protocol C, 2 with protocol D, and a satellite
study using oral gavage with OVX animals.
All studies in all protocols were successful in
detecting increases in uterine weights at one or
more prescribed doses.
Within each protocol, there was overall
agreement among different laboratories both
in the magnitude of the uterine weight
increases and in the MX doses ﬁrst producing
a statistically significant increase in uterine
weight. In protocol A using oral gavage, three
studies detected statistically significant
increases in uterine weights at the LOEL dose
of 20 mg MX/kg/day. Laboratory 12, how-
ever, used only the three intermediate doses
and detected statistically signiﬁcant increases
in uterine weights at its lowest dose of
50 mg/kg/day, where the ratio of relative
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Table 7. Uterine weights, body weights, and ratio of the relative increase in uterine weights for GN in protocol A.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (20 mg/kg/day) (60 mg/kg/day) (120 mg/kg/day) (300 mg/kg/day) (500 mg/kg/day)
1 Wet weight (mg, mean ± SD) 45.9 ± 6.29 64.2 ± 12.02 80.6 ± 7.40 83.9 ± 8.35 92.4 ± 8.19 112.3 ± 28.77
Blotted weight (mg, mean ± SD) 39.1 ± 4.10 55.3 ± 11.49 68.3 ± 7.03 74.7 ± 8.69 81.4 ± 7.85 96.8 ± 24.56
bw (g, mean ± SD) 67.3 ± 2.62 66.3 ± 3.50 66.7 ± 2.81 65.4 ± 5.09 63.6 ± 2.53 63.5 ± 2.30
Absolute ratioa 1.41 1.75 1.91 2.08 2.48
bw adjusted ratiob 1.42* 1.76* 1.97* 2.22* 2.56*
(Lower CL, upper CL)c (1.08, 1.85) (1.35, 2.30) (1.50, 2.58) (1.67, 2.95) (1.93, 3.41)
8 Wet weight (mg, mean ± SD) 23.1 ± 3.25 24.8 ± 3.61 36.2 ± 6.11 51.7 ± 3.99 65.5 ± 9.44 69.8 ± 7.82
Blotted weight (mg, mean ± SD) 21.4 ± 2.56 22.9 ± 3.16 34.1 ± 5.62 49.6 ± 4.09 61.7 ± 8.50 65.7 ± 7.81
bw (g, mean ± SD) 46.5 ± 5.61 40.8 ± 4.34 44.0 ± 4.49 44.4 ± 4.35 42.9 ± 3.98 42.7 ± 4.73
Absolute ratio  1.07 1.59 2.32 2.88 3.07
bw adjusted ratio 1.12 1.61* 2.36* 2.96* 3.16*
(Lower CL, upper CL) (0.91, 1.37) (1.33, 1.96) (1.94, 2.87) (2.42, 3.61) (2.59, 3.86)
9 Wet weight (mg, mean ± SD) 29.7 ± 4.54 39.9 ± 6.49 66.1 ± 13.87 77.0 ± 8.68 74.8 ± 7.25 91.0 ± 15.13
Blotted weight (mg, mean ± SD) 29.2 ± 4.48 39.4 ± 6.53 65.6 ± 13.93 76.3 ± 8.60 74.1 ± 7.23 89.0 ± 13.52
bw (g, mean ± SD) 56.7 ± 2.71 58.0 ± 3.90 57.7 ± 3.61 57.2 ± 2.81 58.1 ± 2.12 56.8 ± 3.31
Absolute ratio  1.35 2.24 2.61 2.53 3.05
bw adjusted ratio 1.36* 2.23* 2.63* 2.57* 3.04*
(Lower CL, upper CL) (1.07, 1.71) (1.77, 2.82) (2.08, 3.31) (2.03, 3.25) (2.41, 3.84)
12 Wet weight (mg, mean ± SD) 24.2 ± 2.48 Not done 58.5 ± 10.89 72.2 ± 12.41 82.8 ± 11.95 Not done
Blotted weight (mg, mean ± SD) 20.6 ± 1.81 52.4 ± 9.89 64.5 ± 11.94 74.6 ± 10.43
bw (g, mean ± SD) 39.7 ± 3.10 40.7 ± 3.30 41.7 ± 4.90 43.4 ± 4.48
Absolute ratio  2.55 3.14 3.63
bw adjusted ratio 2.49* 3.03* 3.47*
(Lower CL, upper CL) (1.97, 3.15) (2.39, 3.85) (2.71, 4.45)
aRatio of arithmetic means of the treated blotted uterine weights relative to the vehicle control blotted uterine weight. bRatio of geometric means of treated blotted uterine weights rela-
tive to the vehicle control blotted uterine weights after adjusting for body weights at necropsy as a covariable. cLower and upper 95% confidence limits for ratio of blotted uterine
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Figure 1. Ratio of the mean blotted uterine weight in response to doses of BPA relative to the vehicle control
group. (A) Participating laboratory results for protocol A using immature female rats, dosing by oral gavage for
3 consecutive days. (B) Participating laboratory results for protocol B using immature female rats, dosing by sc
injection for 3 consecutive days. (C) Participating laboratory results for protocol C using adult OVX rats, dosing
by sc injection for 3 consecutive days. (D) Participating laboratory results for protocol C using adult OVX rats
and extending sc injection dosing to 7 days. In all cases, animals were humanely sacriﬁced 24 hr after the last
dose administration, the uteri were removed and trimmed, and wet and blotted weights were recorded.Mini-Monograph | OECD uterotrophic bioassay validation: dose–response studies
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Table 8. Uterine weights, body weights, and ratio of the relative increase in uterine weights for GN in protocol B.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (1 mg/kg/day) (15 mg/kg/day) (35 mg/kg/day) (50 mg/kg/day) (80 mg/kg/day)
1 Wet weight (mg, mean ± SD) 38.2 ± 10.47 44.5 ± 11.46 62.8 ± 6.75 82.9 ± 14.09 105.2 ± 16.99 120.2 ± 20.31
Blotted weight (mg, mean ± SD) 33.4 ± 9.32 39.6 ± 10.26 58.0 ± 5.64 75.4 ± 11.61 94.2 ± 10.91 105.9 ± 14.33
bw (g, mean ± SD) 63.1 ± 4.45 62.4 ± 3.10 62.8 ± 3.36 62.0 ± 3.18 62.5 ± 3.50 60.8 ± 3.14
Absolute ratio  1.19 1.74 2.26 2.82 3.17
bw adjusted ratio 1.20 1.79* 2.33* 2.91* 3.30*
(Lower CL, upper CL)a (0.90, 1.59) (1.35, 2.38) (1.75, 3.10) (2.19, 3.86) (2.47, 4.42)
8 Wet weight (mg, mean ± SD) 22.6 ± 1.40 26.0 ± 2.28 46.5 ± 9.17 58.8 ± 11.38 67.6 ± 10.51 84.3 ± 8.44
Blotted weight (mg, mean ± SD) 20.9 ± 1.12 24.4 ± 1.87 44.4 ± 8.63 56.4 ± 10.91 64.8 ± 10.08 80.4 ± 7.84
bw (g, mean ± SD) 52.3 ± 5.95 51.1 ± 5.78 51.9 ± 5.34 51.1 ± 5.10 51.6 ± 4.42 52.6 ± 4.92
Absolute ratio  1.17 2.12 2.70 3.10 3.85
bw adjusted ratio 1.18 2.10* 2.69* 3.08* 3.83*
(Lower CL, upper CL) (0.96, 1.45) (1.71, 2.58) (2.19, 3.30) (2.51, 3.79) (3.12, 4.71)
9 Wet weight (mg, mean ± SD) 34.9 ± 3.47 41.3 ± 8.49 65.9 ± 4.95 89.9 ± 4.69 106.7 ± 7.71 145.3 ± 29.46
Blotted weight (mg, mean ± SD) 34.1 ± 3.67 40.0 ± 8.20 64.7 ± 5.18 88.7 ± 4.61 104.1 ± 7.12 120.0 ± 13.10
bw (g, mean ± SD) 58.0 ± 2.27 57.1 ± 3.54 57.7 ± 3.30 59.3 ± 3.89 57.2 ± 1.99 58.4 ± 2.84
Absolute ratio  1.18 1.90 2.61 3.06 3.52
bw adjusted ratio 1.18* 1.91* 2.57* 3.10* 3.50*
(Lower CL, upper CL) (1.0006b, 1.38) (1.63, 2.25) (2.19, 3.02) (2.63, 3.64) (2.98, 4.11)
12 Wet weight (mg, mean ± SD) 26.8 ± 6.97 Not done 41.7 ± 8.36 55.9 ± 13.68 66.2 ± 14.75 Not done
Blotted weight (mg, mean ± SD) 22.4 ± 6.47 35.2 ± 9.19 50.6 ± 10.96 59.4 ± 12.36
bw (g, mean ± SD) 40.4 ± 3.38 42.1 ± 5.40 40.6 ± 4.57 40.3 ± 3.58
Absolute ratio  1.57 2.26 2.65
bw adjusted ratio 1.48* 2.28* 2.70*
(Lower CL, upper CL) (1.10, 1.98) (1.70, 3.05) (2.02, 3.61)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. bWith the lower 95% conﬁdence limit > 1.0, the result is statistically
signiﬁcant. *Level of signiﬁcance, p < 0.05.
Table 9. Uterine weights, body weights, and ratio of the relative increase in uterine weights for GN in protocol C.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (1 mg/kg/day) (15 mg/kg/day) (35 mg/kg/day) (50 mg/kg/day) (80 mg/kg/day)
1 Wet weight (mg, mean ± SD) 93.5 ± 12.30 84.0 ± 7.86 144.7 ± 18.42 162.6 ± 13.97 151.0 ± 14.35 177.6 ± 40.11
Blotted weight (mg, mean ± SD) 85.9 ± 13.10 77.2 ± 6.44 131.5 ± 15.40 151.6 ± 13.14 142.1 ± 11.98 163.4 ± 33.74
bw (g, mean ± SD) 272.5 ± 20.75 277.0 ± 13.53 275.5 ± 14.15 270.4 ± 14.70 267.4 ± 10.96 272.4 ± 15.03
Absolute ratio  0.90 1.53 1.77 1.65 1.90
bw adjusted ratio 0.90 1.53* 1.78* 1.68* 1.89*
(Lower CL, upper CL)a (0.74, 1.10) (1.25, 1.88) (1.46, 2.18) (1.37, 2.05) (1.54, 2.31)
9 Wet weight (mg, mean ± SD) 87.2 ± 11.74 85.9 ± 10.39 136.9 ± 23.21 161.4 ± 7.49 181.0 ± 17.13 172.6 ± 13.57
Blotted weight (mg, mean ± SD) 86.3 ± 11.88 85.0 ± 10.35 135.8 ± 22.92 160.1 ± 7.33 179.4 ± 16.71 170.6 ± 11.92
bw (g, mean ± SD) 256.1 ± 8.87 257.9 ± 10.05 258.4 ± 9.90 255.2 ± 11.14 253.3 ± 12.09 253.6 ± 10.56
Absolute ratio  0.99 1.57 1.86 2.08 1.98
bw adjusted ratio 0.99 1.57* 1.87* 2.08* 1.98*
(Lower CL, upper CL) (0.83, 1.18) (1.32, 1.88) (1.56, 2.23) (1.74, 2.48) (1.66, 2.37)
12 Wet weight (mg, mean ± SD) 106.0 ± 18.84 Not done 146.1 ± 33.23 162.2 ± 26.36 183.3 ± 57.85 Not done
Blotted weight (mg, mean ± SD) 98.6 ± 22.04 133.9 ± 30.80 152.0 ± 24.29 168.3 ± 54.04
bw (g, mean ± SD) 297.2 ± 14.54 303.6 ± 12.80 297.2 ± 17.70 303.4 ± 17.97
Absolute ratio  1.36 1.54 1.71
bw adjusted ratio 1.31 1.56* 1.62*
(Lower CL, upper CL) (0.92, 1.87) (1.09, 2.21) (1.14, 2.32)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance, p < 0.05.
Table 10. Uterine weights, body weights, and ratio of the relative increase in uterine weights for GN in protocol D.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (1 mg/kg/day) (15 mg/kg/day) (35 mg/kg/day) (50 mg/kg/day) (80 mg/kg/day)
1 Wet weight (mg, mean ± SD) 96.4 ± 17.25 96.9 ± 15.94 161.8 ± 20.55 207.8 ± 29.01 222.0 ± 29.72 394.0 ± 75.24
Blotted weight (mg, mean ± SD) 87.2 ± 15.17 85.8 ± 11.09 145.8 ± 19.66 189.3 ± 22.50 200.0 ± 25.22 303.6 ± 24.41
bw (g, mean ± SD) 281.5 ± 19.95 268.8 ± 13.92 270.2 ± 14.68 264.2 ± 14.56 266.4 ± 12.93 265.3 ± 12.31
Absolute ratio  0.98 1.67 2.17 2.29 3.48
bw adjusted ratio 0.99 1.67* 2.20* 2.31* 3.55*
(Lower CL, upper CL)a (0.80, 1.23) (1.35, 2.07) (1.78, 2.73) (1.87, 2.86) (2.87, 4.40)
9 Wet weight (mg, mean ± SD) 76.8 ± 4.59 90.9 ± 9.17 157.5 ± 21.51 193.5 ± 12.44 209.9 ± 11.29 243.8 ± 76.43
Blotted weight (mg, mean ± SD) 75.9 ± 4.97 89.7 ± 9.13 156.7 ± 21.76 192.4 ± 11.73 208.7 ± 10.70 215.3 ± 37.35
bw (g, mean ± SD) 282.1 ± 12.40 282.6 ± 11.72 276.9 ± 12.39 280.2 ± 10.44 277.1 ± 12.44 275.3 ± 12.18
Absolute ratio  1.18 2.06 2.53 2.75 2.84
bw adjusted ratio 1.18 2.06* 2.54* 2.75* 2.81*
(Lower CL, upper CL) (0.9995b, 1.39) (1.74, 2.43) (2.15, 2.99) (2.33, 3.25) (2.38, 3.32)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. bWith the lower 95% conﬁdence limit not > 1.0, the result is not sta-
tistically signiﬁcant. *Level of signiﬁcance, p < 0.05.increase in uterine weight was already
approaching 4 (Table 12). In protocol B, four
studies detected statistically significant
increases in uterine weights at the second dose
of 100 mg MX/kg/day (Table 13). In proto-
cols C and D, all studies detected statistical
significance at the second dose of 100 mg
MX/kg/day (Tables 14 and 15). The satellite
study with OVX animals using oral gavage
administration detected statistically signiﬁcant
increases in uterine weight at the lowest of the
three intermediate doses used in that study,
50 mg/kg/day (i.e., the lowest 20-mg
MX/kg/day dose was not tested in this labora-
tory with this protocol) (Table 16).
The MX results, except for the satellite
study, are shown graphically in Figure 3. In
protocol A, all studies at the lowest dose had
ratios of the maximum mean uterine weights
of the treated groups to the controls of 2 to
3.5. Thus, the selected doses were unable to
indicate a minimal effective dose. In the case
of MX, the oral route of administration was
more sensitive than sc injection (Table 12). In
protocols B, C, and D, the lowest dose pro-
ducing a statistically significant increase in
uterine weights was similar (Tables 13–15).
However, protocol B produced a somewhat
higher ratio of the maximum mean uterine
weights relative to the controls of 2.5 to 3.5.
The extended, 7-day dosing in protocol D
did not lead to any increase in the maximum
increase in uterine weights in the case of MX.
With MX, the dose–response curves of proto-
col B appeared to be more variable than pro-
tocols C and D (Figure 3). The satellite study
with OVX animals using oral gavage adminis-
tration detected statistically significant
increases in uterine weight at the lowest of the
three intermediate doses used in that study,
60 mg/kg/day (i.e., the lowest 20-mg
MX/kg/day dose was not tested in this labora-
tory with this protocol) (Table 16).
Nonylphenol. A total of 22 dose–response
studies were conducted with NP, including 4
with protocol A, 10 with protocol B, 5 with
protocol C, 2 with protocol D, and a satellite
study using oral gavage with OVX animals.
Three of the 21 NP studies were unsuccessful
in detecting increases in uterine weights at
any of the prescribed doses. Again, laboratory
21 did not record the required terminal body
weights, and these studies could not be
statistically analyzed using body weight
adjustment. However, the wet and blotted
uterine results are included in Table 18 and
Figure 4, and these have been statistically
compared without body weight adjustment.
Within each protocol, there was overall
agreement among different laboratories both
in the magnitude of the uterine weight
increases and in the NP doses ﬁrst producing a
statistically significant increase in uterine
weight. In protocol A using oral gavage, all
four studies detected statistically significant
increases in uterine weights at LOEL doses of
75 mg NP/kg/day (Table 17). In protocol B,
seven of nine studies detected statistically sig-
niﬁcant increases in uterine weights at doses of
35 mg NP/kg/day (one study), 80 mg/kg/day
(ﬁve studies), and 100 mg/kg/day (one study).
One of two laboratories that failed to detect a
significantly increased uterine weight used
only the three intermediate doses and did not
use the highest dose (Table 18). In protocol C,
four of ﬁve studies detected statistical signiﬁ-
cant increases in uterine weights at doses of 35
mg NP/kg/day (one study), 80 mg/kg/day
(one study) and 100 mg/kg/day (two studies)
(Table 19). The laboratory that failed to
detect a signiﬁcant increase in uterine weight
used only the three intermediate doses and did
not use the highest dose. In protocol D, both
studies detected statistical significance at a
dose of 35 mg NP/kg/day (Table 20). The
satellite study with OVX animals using oral
gavage administration detected statistically sig-
niﬁcant increases in uterine weight at the low-
est of the three intermediate doses used in that
study, 75 mg/kg/day (i.e., the lowest 15-mg
NP/kg/day dose was not tested in this labora-
tory with this protocol) (Table 21).
The NP results, except for the satellite
study, are shown graphically in Figure 4. In
protocol A using oral gavage, the ratio of the
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Figure 2. Ratio of the mean absolute blotted uterine weight in response to doses of GN relative to the vehi-
cle control group. (A) Participating laboratory results for protocol A using immature female rats, dosing by
oral gavage for 3 consecutive days. (B) Participating laboratory results for protocol B using immature
female rats, dosing by sc injection for 3 consecutive days. (C) Participating laboratory results for protocol C
using adult OVX rats, dosing by sc injection for 3 consecutive days. (D) Participating laboratory results for
protocol C using adult OVX rats and extending sc injection dosing to 7 days. In all cases, animals were
humanely sacriﬁced 24 hr after the last dose administration, the uteri were removed and trimmed, and wet
and blotted weights were recorded.
Table 11. Uterine weights, body weights, and ratio of the relative increase in uterine weights for GN in satellite OVX protocol by oral gavage.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (20 mg/kg/day) (60 mg/kg/day) (120 mg/kg/day) (300 mg/kg/day) (500 mg/kg/day)
12 Wet weight (mg, mean ± SD) 101.1 ± 16.93 Not done 194.5 ± 50.41 191.7 ± 43.16 270.9 ± 92.51 Not done
Blotted weight (mg, mean ± SD) 95.0 ± 16.43 172.6 ± 38.92 178.9 ± 39.60 195.1 ± 20.90
bw (g, mean ± SD) 295.5 ± 11.09 291.2 ± 12.85 285.7 ± 6.30 283.4 ± 12.36
Absolute ratio  1.82 1.88 2.05
bw adjusted ratio 1.83* 1.93* 2.16*
(Lower CL, upper CL)a (1.34, 2.48) (1.40, 2.66) (1.55, 3.00)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance, p < 0.05.maximum mean uterine weights of the treated
groups to the controls was generally between 2
and 3 for the treated groups relative to the
controls. The ratio of treated to vehicle groups
was 1.5 to 3 in protocol B, a more modest 1.5
in protocol C, and 2 by extending the dosing
to 7 days in protocol D. Again, dose–response
curves among laboratories in protocol B
appeared to be more variable than protocols C
and D (Figure 4).
o,p´-DDT. A total of 14 dose–response
studies were conducted with o,p´-DDT,
including 4 with protocol A, 4 with
protocol B, 3 with protocol C, 2 with protocol
D, and a satellite study using oral gavage with
OVX animals. Thirteen of the 14 studies were
successful in detecting increases in uterine
weights at one or more prescribed doses.
Within each protocol, there was overall agree-
ment among different laboratories both in the
magnitude of the uterine weight increases and
in the o,p´-DDT doses ﬁrst producing a statis-
tically signiﬁcant increase in uterine weight. In
protocol A using oral gavage, one study
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Table 12. Uterine weights, body weights, and ratio of the relative increase in uterine weights for MX in protocol A.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (20 mg/kg/day) (50 mg/kg/day) (120 mg/kg/day) (300 mg/kg/day) (500 mg/kg/day)
1 Wet weight (mg, mean ± SD) 44.3 ± 6.44 88.2 ± 17.18 104.5 ± 13.59 103.4 ± 11.55 112.6 ± 8.44 114.3 ± 6.37
Blotted weight (mg, mean ± SD) 38.4 ± 6.50 76.4 ± 16.74 87.1 ± 11.13 86.2 ± 7.74 93.1 ± 7.50 98.8 ± 5.14
bw (g, mean ± SD) 61.6 ± 2.49 61.4 ± 3.78 61.1 ± 1.84 61.1 ± 3.57 59.2 ± 2.21 58.0 ± 2.96
Absolute ratioa 1.99 2.27 2.25 2.43 2.58
bw adjusted ratiob 1.98* 2.31* 2.30* 2.59* 2.83*
(Lower CL, upper CL)c (1.65, 2.39) (1.91, 2.79) (1.90, 2.77) (2.13, 3.15) (2.31, 3.46)
3 Wet weight (mg, mean ± SD) 34.6 ± 3.93 74.7 ± 10.74 90.7 ± 10.65 98.5 ± 9.11 108.8 ± 9.62 98.0 ± 16.90
Blotted weight (mg, mean ± SD) 32.6 ± 4.23 72.2 ± 10.22 90.8 ± 9.67 94.7 ± 8.91 105.0 ± 9.75 94.8 ± 15.37
bw (g, mean ± SD) 62.9 ± 1.64 62.2 ± 3.38 62.0 ± 3.04 62.1 ± 3.44 58.4 ± 3.31 58.0 ± 4.00
Absolute ratio  1.82 2.29 2.39 2.65 2.39
bw adjusted ratio 1.88* 2.37* 2.47* 2.94* 2.65*
(Lower CL, upper CL) (1.52, 2.31) (1.92, 2.93) (2.00, 3.05) (2.34, 3.69) (2.11, 3.35)
12 Wet weight (mg, mean ± SD) 24.2 ± 2.48 Not done 89.3 ± 26.37 88.3 ± 17.06 86.3 ± 10.42 Not done
Blotted weight (mg, mean ± SD) 20.6 ± 1.81 79.6 ± 24.95 77.9 ± 14.63 78.6 ± 10.02
bw (g, mean ± SD) 39.7 ± 3.10 39.8 ± 5.76 39.2 ± 3.38 38.3 ± 3.30
Absolute ratio  3.87 3.79 3.83
bw adjusted ratio 3.71* 3.88* 3.98*
(Lower CL, upper CL) (2.87, 4.79) (2.93, 4.90) (3.07, 5.15)
14 Wet weight (mg, mean ± SD) 18.4 ± 2.19 58.3 ± 16.27 55.2 ± 8.01 65.4 ± 8.20d 63.4 ± 11.41d 62.0 ± 4.58d
Blotted weight (mg, mean ± SD) 14.8 ± 2.28 51.0 ± 12.98 45.2 ± 8.13 59.2 ± 9.65 55.6 ± 8.20 51.7 ± 3.79
bw (g, mean ± SD) 40.3 ± 6.83 45.8 ± 4.26 40.5 ± 4.69 48.2 ± 5.81 46.3 ± 5.47 47.6 ± 4.17
Absolute ratio  3.45 3.05 4.00 3.76 3.49
bw adjusted ratio 3.14* 3.03* 3.59* 3.46* 3.19*
(Lower CL, upper CL) (2.31, 4.26) (2.27, 4.05) (2.57, 5.01) (2.51, 4.77) (2.19, 4.63)
aRatio of arithmetic means of the treated blotted uterine weights relative to the vehicle control blotted uterine weights. bRatio of geometric means of treated blotted uterine weights rela-
tive to the vehicle control blotted uterine weights after adjusting for body weights at necropsy as a covariable. cLower and upper 95% confidence limits for ratio of blotted uterine
weights based on body weights as a covariable. dOne animal died in 120 mg MX/kg/day group before necropsy; one animal died in 300 mg MX/kg/day group before necropsy; three ani-
mals died in 500 mg MX/kg/day group before necropsy; and one animal also died in the vehicle control group before necropsy. *Level of signiﬁcance, p < 0.05.
Table 13. Uterine weights, body weights, and ratio of the relative increase in uterine weights for MX in protocol B.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (20 mg/kg/day) (100 mg/kg/day) (250 mg/kg/day) (500 mg/kg/day) (800 mg/kg/day)
1 Wet weight (mg, mean ± SD) 39.7 ± 7.58 44.9 ± 9.18 52.4 ± 9.38 77.0 ± 13.82 99.3 ± 17.57 103.4 ± 6.86
Blotted weight (mg, mean ± SD) 35.2 ± 6.34 40.9 ± 8.42 48.0 ± 9.43 68.0 ± 11.28 86.3 ± 10.15 93.5 ± 6.15
bw (g, mean ± SD) 66.6 ± 4.48 65.0 ± 3.87 65.4 ± 4.20 65.5 ± 3.69 64.7 ± 2.92 64.8 ± 3.84
Absolute ratio  1.16 1.36 1.93 2.45 2.66
bw adjusted ratio 1.16 1.36* 1.94* 2.47* 2.69*
(Lower CL, upper CL)a (0.89, 1.50) (1.05, 1.76) (1.50, 2.51) (1.91, 3.21) (2.08, 3.49)
3 Wet weight (mg, mean ± SD) 34.2 ± 3.49 47.1 ± 6.83 86.2 ± 19.85 108.9 ± 20.26 121.9 ± 30.68 139.7 ± 10.78
Blotted weight (mg, mean ± SD) 31.5 ± 3.97 45.1 ± 6.82 81.0 ± 16.97 101.4 ± 16.06 107.4 ± 17.90 132.2 ± 9.09
bw (g, mean ± SD) 63.5 ± 3.92 63.2 ± 2.13 62.6 ± 1.54 61.5 ± 3.38 62.3 ± 2.59 63.8 ± 1.54
Absolute ratio  1.20 2.16 2.70 2.86 3.52
bw adjusted ratio 1.21 2.21* 2.88* 2.98* 3.52*
(Lower CL, upper CL) (0.9911b, 1.49) (1.80, 2.71) (2.34, 3.55) (2.42, 3.65) (2.87, 4.31)
12 Wet weight (mg, mean ± SD) 26.8 ± 6.97 Not done 71.3 ± 10.13 89.2 ± 8.98 83.2 ± 10.60 Not done
Blotted weight (mg, mean ± SD) 22.4 ± 6.47 62.3 ± 9.23 76.2 ± 38.60 72.0 ± 9.42
bw (g, mean ± SD) 40.4 ± 3.38 39.7 ± 6.98 39.6 ± 1.66 38.7 ± 5.27
Absolute ratio  2.78 3.40 3.21
bw adjusted ratio 2.86* 3.53* 3.34*
(Lower CL, upper CL) (2.18, 3.77) (2.68, 4.65) (2.53, 4.40)
14 Wet weight (mg, mean ± SD) 18.3 ± 3.61 23.5 ± 4.18 40.8 ± 14.58 58.2 ± 13.33 74.3 ± 18.48 72.6 ± 21.34
Blotted weight (mg, mean ± SD) 16.3 ± 3.78 17.8 ± 4.54 27.7 ± 6.28 44.3 ± 12.34 61.8 ± 13.12 60.2 ± 7.60
bw (g, mean ± SD) 44.2 ± 5.25 44.7 ± 4.52 46.4 ± 4.97 40.7 ± 9.15 44.7 ± 5.00 46.8 ± 4.49
Absolute ratio  1.09 1.69 2.71 3.79 3.69
bw adjusted ratio 1.07 1.62* 2.89* 3.76* 3.56*
(Lower CL, upper CL) (0.79, 1.45) (1.20, 2.19) (2.13, 3.93) (2.78, 5.09) (2.58, 4.88)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. bWith the lower 95% conﬁdence limit not > 1.0, the result is not sta-
tistically signiﬁcant. *Level of signiﬁcance, p < 0.05.detected statistically significant increases in
uterine weights at a LOEL dose of 10 mg
DDT/kg/day, and three studies at 50
mg/kg/day (Table 22). In protocol B, one
study detected statistically signiﬁcant increases
at a dose of 100 mg DDT/kg/day, and the
other three laboratories achieved statistical
significance at doses of 200 mg/kg/day
(Table 23). In protocol C, one study detected
statistical significance at a dose of 50 mg
DDT/kg/day and one study at a dose of 100
mg/kg/d (Table 24). The laboratory that did
not achieve statistical significance used only
the three intermediate doses and did not use
the high dose of 200 mg/kg/day. In protocol
D, one study detected statistical signiﬁcance at
a dose of 50 mg DDT/kg/day and the other at
a dose of 100 mg/kg/day (Table 25). The
satellite study with OVX animals using oral
gavage administration detected statistically sig-
niﬁcant increases in uterine weight at the low-
est of the three intermediate doses used in that
study, 50 mg/kg/day (i.e., the lowest 10-mg
DDT/kg/day dose was not tested in this labo-
ratory with this protocol) (Table 26).
The o,p´-DDT results, except for the
satellite study, are shown graphically in Figure
5. In protocol A using oral gavage, the ratio of
the maximum mean uterine weights of the
treated groups to the controls was generally
between 2.5 and 3.5 and plateaued at the sec-
ond-highest dose of 300 mg/kg/day. In proto-
cols B, C, and D, the ratio in uterine weights
was approximately 1.5. Extending the dosing
to 7 days did not lead to an apparent increase
in the maximum induction in uterine
weights. Within the sc protocols, there was no
apparent difference in variability of the
dose–response curves between the intact,
immature, and OVX animals.
Discussion and Conclusions
Reproducibility of the dose response among
laboratories within a given protocol was good.
It is noteworthy that this reproducibility was
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Table 14. Uterine weights, body weghts, and ratio of the relative increase in uterine weights for MX in protocol C.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (20 mg/kg/day) (100 mg/kg/day) (250 mg/kg/day) (500 mg/kg/day) (800 mg/kg/day)
1 Wet weight (mg, mean ± SD) 92.1 ± 8.86 88.5 ± 6.03 118.3 ± 15.22 173.3 ± 34.90 256.7 ± 80.39 282.1 ± 90.49
Blotted weight (mg, mean ± SD) 84.9 ± 8.03 81.4 ± 6.04 108.3 ± 13.16 156.5 ± 25.31 197.1 ± 46.05 203.3 ± 34.71
bw (g, mean ± SD) 255.9 ± 10.19 259.4 ± 16.10 251.7 ± 9.52 249.3 ± 9.53 248.8 ± 11.64 246.6 ± 13.26
Absolute ratio  0.96 1.28 1.84 2.32 2.39
bw adjusted ratio 0.95 1.28* 1.85* 2.32* 2.42*
(Lower CL, upper CL)a (0.77, 1.19) (1.03, 1.59) (1.49, 2.31) (1.86, 2.89) (1.93, 3.02)
3 Wet weight (mg, mean ± SD) 90.8 ± 8.37 97.1 ± 8.47 155.7 ± 19.42 184.4 ± 33.95 298.4 ± 126.20 298.9 ± 56.93
Blotted weight (mg, mean ± SD) 85.5 ± 8.57 92.5 ± 8.93 149.1 ± 18.59 173.6 ± 30.05 212.0 ± 27.48 226.2 ± 23.49
bw (g, mean ± SD) 278.5 ± 11.15 278.7 ± 10.33 2727.1 ± 15.33 272.4 ± 10.41 264.2 ± 12.98 264.5 ± 12.62
Absolute ratio  1.08 1.74 2.03 2.48 2.64
bw adjusted ratio 1.08 1.72* 1.99* 2.42* 2.59*
(Lower CL, upper CL) (0.89, 1.32) (1.41, 2.10) (1.63, 2.43) (1.96, 2.98) (2.10, 3.19)
12 Wet weight (mg, mean ± SD) 106.0 ± 18.84 Not done 170.2 ± 31.93 196.8 ± 48.65 214.6 ± 24.88 Not done
Blotted weight (mg, mean ± SD) 98.6 ± 22.04 155.8 ± 32.81 171.7 ± 36.49 185.0 ± 22.30
bw (g, mean ± SD) 297.2 ± 14.54 287.4 ± 16.77 290.0 ± 12.36 288.7 ± 9.24
Absolute ratio  1.58 1.74 1.88
bw adjusted ratio 1.63* 1.79* 1.95*
(Lower CL, upper CL) (1.21, 2.19) (1.33, 2.39) (1.45, 2.62)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance, p < 0.05.
Table 15. Uterine weights, body weights, and ratio of the relative increase in uterine weights for MX in protocol D.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (20 mg/kg/day) (100 mg/kg/day) (250 mg/kg/day) (500 mg/kg/day) (800 mg/kg/day)
1 Wet weight (mg, mean ± SD) 98.1 ± 15.43 90.6 ± 11.93 128.1 ± 28.27 167.9 ± 32.11 254.0 ± 61.79 246.9 ± 30.58
Blotted weight (mg, mean ± SD) 90.8 ± 15.92 84.8 ± 10.43 121.2 ± 26.36 155.9 ± 28.39 211.9 ± 41.21 216.7 ± 27.12
bw (g, mean ± SD) 272.1 ± 14.66 271.6 ± 16.86 237.2 ± 14.85 251.4 ± 14.90 246.5 ± 17.59 245.8 ± 14.41
Absolute ratio  0.93 1.34 1.72 2.33 2.39
bw adjusted ratio 0.94 1.33* 1.75* 2.38* 2.46*
(Lower CL, upper CL)a (0.72, 1.23) (1.02, 1.75) (1.30, 2.34) (1.76, 3.22) (1.82, 3.34)
3 Wet weight (mg, mean ± SD) 96.8 ± 6.73 104.3 ± 5.76 151.0 ± 26.12 237.7 ± 29.06 238.8 ± 40.63 252.0 ± 34.97
Blotted weight (mg, mean ± SD) 92.6 ± 5.87 99.3 ± 4.97 144.6 ± 25.61 221.2 ± 20.14 228.2 ± 38.44 246.9 ± 30.58
bw (g, mean ± SD) 282.7 ± 19.53 277.6 ± 17.55 265.2 ± 18.00 256.6 ± 14.68 254.7 ± 8.95 250.9 ± 10.80
Absolute ratio  1.07 1.56 2.39 2.46 2.59
bw adjusted ratio 1.08 1.55* 2.41* 2.47* 2.61*
(Lower CL, upper CL) (0.89, 1.30) (1.27, 1.90) (1.94, 2.98) (1.98, 3.06) (2.08, 3.26)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance, p < 0.05.
Table 16. Uterine weights, body weights, and ratio of the relative increase in uterine weights for MX in satellite OVX protocol by oral gavage.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (20 mg/kg/day) (50 mg/kg/day) (120 mg/kg/day) (300 mg/kg/day) (500 mg/kg/day)
12 Wet weight (mg, mean ± SD) 101.1 ± 16.93 Not done 247.1 ± 20.31 301.8 ± 54.21 388.6 ± 1.8.89 Not done
Blotted weight (mg, mean ± SD) 95.0 ± 16.43 194.7 ± 33.94 217.1 ± 16.75 231.8 ± 23.71
bw (g, mean ± SD) 295.5 ± 11.09 278.7 ± 12.96 275.0 ± 11.90 279.0 ± 9.69
Absolute ratio  2.05 2.29 2.44
bw adjusted ratio 2.11* 2.36* 2.50*
(Lower CL, upper CL)a (1.71, 2.60) (1.89, 2.94) (2.03, 3.08)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance, p < 0.05.achieved under a variety of different study
conditions (e.g., strain, diet, housing protocol,
bedding, vehicle); modest differences in the
age of the immature animals (pnd 18–20), age
at ovariectomy, and time of regression after
ovariectomy; and a signiﬁcant range in labora-
tory experience and proficiency (Table 27).
For example, some laboratories have con-
ducted uterotrophic studies for several years,
whereas a number of others were conducting
the bioassay for only for the first or second
time. These variations and possible difference
in experience would be expected to contribute
to some degree of variability for a given proto-
col. In this light, the good reproducibility
observed suggests that the uterotrophic bioas-
say itself is robust. This reproducibility is simi-
lar to that observed in phase 1 using the
potent reference estrogen EE (Kanno et al.
2001). In addition, the uterine increase is
observed even under conditions of severe sys-
temic toxicity, as evidenced by mortalities and
decreases in body weights sometimes greater
than 10% (Tables 2D, 4D, 5A, and 6A). This
easily observed response at doses exceeding the
maximum tolerated dose further supports that
the uterotrophic assay is a robust screen for
detecting possible estrogen agonists.
For all protocols, the blotted uterine
weights appeared to show less interlaboratory
and intragroup variability than uterine wet
weight. This suggests that the blotted weight
will provide greater power for detecting
uterotrophic effects than wet weight.
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Figure 3. Ratio of the mean absolute blotted uterine weight in response to doses of MX relative to the vehi-
cle control group. (A) Participating laboratory results for protocol A using immature female rats, dosing by
oral gavage for 3 consecutive days. (B) Participating laboratory results for protocol B using immature
female rats, dosing by sc injection for 3 consecutive days. (C) Participating laboratory results for protocol
C using adult OVX rats, dosing by sc injection for 3 consecutive days. (D) Participating laboratory results
for protocol C using adult OVX rats and extending sc injection dosing to 7 days. In all cases, animals were
humanely sacriﬁced 24 hr after the last dose administration, the uteri were removed and trimmed, and wet
and blotted weights were recorded.
Table 17. Uterine weights, body weights, and ratio of the relative increase in uterine weights for NP in protocol A.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (15 mg/kg/day) (75 mg/kg/day) (125 mg/kg/day) (250 mg/kg/day) (350 mg/kg/day)
4 Wet weight (mg, mean ± SD) 31.3 ± 10.31 30.8 ± 5.42 50.5 ± 10.54 52.5 ± 5.72 62.3 ± 8.02a See notea
Blotted weight (mg, mean ± SD) 29.3 ± 10.91 28.7 ± 4.68 45.2 ± 5.98 49.3 ± 5.89 60.3 ± 6.99
bw (g, mean ± SD) 42.7 ± 2.91 38.8 ± 7.12 39.7 ± 3.49 36.3 ± 5.00 28.5 ± 1.55
Absolute ratiob 0.98 1.54 1.68 2.05
Boy weight Adjusted Ratioc 1.07 1.68* 1.91* 2.61*
(Lower CL, upper CL)d (0.80, 1.43) (1.26, 2.22) (1.40, 2.61) (1.69, 4.04)
7 Wet weight (mg, mean ± SD) 31.4 ± 2.47 33.0 ± 4.42 44.8 ± 7.36 49.8 ± 4.24 65.3 ± 10.10e 69.2 ± 8.66e
Blotted weight (mg, mean ± SD) 30.0 ± 2.30 31.8 ± 4.34 43.5 ± 7.07 48.1 ± 4.13 62.8 ± 9.44 64.6 ± 8.30
bw (g, mean ± SD) 57.8 ± 3.50 56.6 ± 4.97 54.3 ± 4.61 55.5 ± 4.50 49.8 ± 7.12 43.8 ± 4.57
Absolute ratio  1.06 1.45 1.60 2.09 2.15
bw adjusted ratio 1.06 1.46* 1.62* 2.17* 2.32*
(Lower CL, upper CL) (0.87, 1.30) (1.19, 1.80) (1.32, 1.98) (1.72, 2.74) (1.71, 3.12)
9 Wet weight (mg, mean ± SD) 29.7 ± 4.54 36.9 ± 7.82 42.5 ± 5.30 60.2 ± 11.17 58.1 ± 9.28 60.6 ± 4.03f
Blotted weight (mg, mean ± SD) 29.2 ± 4.48 36.4 ± 7.80 42.0 ± 5.36 59.7 ± 11.14 57.6 ± 8.98 60.0 ± 4.22
bw (g, mean ± SD) 56.7 ± 2.71 59.0 ± 2.29 58.3 ± 3.16 57.0 ± 3.11 47.1 ± 9.55 33.8 ± 3.83
Absolute ratio  1.24 1.44 2.04 1.97 2.05
bw adjusted ratio 1.20 1.42* 2.02* 2.17* 2.61*
(Lower CL, upper CL) (0.94, 1.54) (1.11, 1.81) (1.59, 2.58) (1.62, 2.90) (1.61, 4.23)
12 Wet weight (mg, mean ± SD) 24.2 ± 2.48 Not done 50.5 ± 10.39 45.0 ± 9.30 66.9 ± 20.29g Not done
Blotted weight (mg, mean ± SD) 20.6 ± 1.81 45.5 ± 9.22 42.0 ± 7.85 62.2 ± 18.95
bw (g, mean ± SD) 39.7 ± 3.10 44.1 ± 4.91 40.5 ± 3.44 39.9 ± 2.05
Absolute ratio  2.21 1.91 3.03
bw adjusted ratio 1.96* 1.85* 2.95*
(Lower CL, upper CL) (1.45, 2.64) (1.41, 2.42) (2.02, 4.32)
aTwo animals died in 250 mg NP/kg/day group before necropsy; all animals died in 350 mg NP/kg/day group before necropsy. bRatio of arithmetic means of the treated blotted uterine
weights relative to the vehicle control blotted uterine weights. cRatio of geometric means of treated blotted uterine weights relative to the vehicle control blotted uterine weights after
adjusting for body weights at necropsy as a covariable. dLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. eOne animal
died in 250 mg NP/kg/day group before necropsy; three animals died in 350 mg NP/kg/day group before necropsy. fThree animals died in 350 mg NP/kg/day group before necropsy. gFour
animals died in 250 mg NP/kg/day group before necropsy. *Level of signiﬁcance, p < 0.05.Nevertheless, the wet weight and blotted
weights were generally consistent in achiev-
ing statistical significance. Again, this out-
come is identical to that of phase 1 using the
potent reference estrogen EE, where the blot-
ted weights were slightly less variable than
the wet weights (Kanno et al. 2001).
Additionally, the observation was made that
wet and blotted weights in the rat vary by
only a few milligrams with both EE and the
weak agonists employed here, as long as the
relative ratio of the uterine increase is about 2
or less. As the relative ratio exceeds 2, a rapid
increase in the quantity of imbibed intra-
luminal fluid occurs. This was true with EE
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Table 18. Uterine weights, body weights, and ratio of the relative increase in uterine weights for NP in protocol B.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (5 mg/kg/day) (15 mg/kg/day) (35 mg/kg/day) (80 mg/kg/day) (100 mg/kg/day)
4 Wet weight (mg, mean ± SD) 34.7 ± 3.47 34.3 ± 7.89 29.7 ± 2.88 37.2 ± 2.40 64.5 ± 18.51 53.5 ± 13.49
Blotted weight (mg, mean ± SD) 34.1 ± 3.67 31.3 ± 7.53 28.2 ± 3.76 34.0 ± 4.00 61.5 ± 17.41 51.2 ± 13.23
bw (g, mean ± SD) 45.6 ± 3.93 45.3 ± 3.88 44.1 ± 3.88 44.8 ± 2.73 44.4 ± 3.26 44.0 ± 2.91
Absolute ratio  1.02 0.91 1.10 1.99 1.66
bw adjusted ratio 1.04 0.97 1.16 2.05* 1.72*
(Lower CL, upper CL)a (0.73, 1.48) (0.68, 1.38) (0.81, 1.65) (1.44, 2.92) (1.21, 2.46)
6 Wet weight (mg, mean ± SD) 61.1 ± 15.24 Not done 52.7 ± 17.14 66.7 ± 12.35 79.5 ± 37.03 Not done
Blotted weight (mg, mean ± SD) 58.0 ± 14.00 50.5 ± 16.83 62.4 ± 12.38 75.5 ± 33.32
bw (g, mean ± SD) 48.9 ± 8.15 49.2 ± 11.85 50.8 ± 6.52 48.8 ± 8.97
Absolute ratio  0.87 1.08 1.30
bw adjusted ratio 0.84 1.03 1.24
(Lower CL, upper CL) (0.62, 1.13) (0.76, 1.40) (0.91, 1.68)
7 Wet weight (mg, mean ± SD) 30.7 ± 4.18 32.2 ± 3.35 37.1 ± 5.53 34.9 ± 7.49 52.5 ± 13.23 68.1 ± 7.85
Blotted weight (mg, mean ± SD) 29.6 ± 3.85 31.0 ± 3.29 35.8 ± 5.36 33.8 ± 7.27 50.9 ± 12.73 66.3 ± 7.69
bw (g, mean ± SD) 57.2 ± 4.01 57.0 ± 3.13 56.8 ± 4.30 57.4 ± 4.17 57.4 ± 4.20 57.0 ± 3.02
Absolute ratio  1.05 1.21 1.14 1.72 2.24
bw adjusted ratio 1.05 1.22 1.12 1.68* 2.25*
(Lower CL, upper CL) (0.85, 1.30) (0.99, 1.50) (0.91, 1.39) (1.36, 2.08) (1.83, 2.78)
8 Wet weight (mg, mean ± SD) 26.0 ± 3.06 23.9 ± 2.69 26.1 ± 2.13 29.2 ± 1.59 37.0 ± 9.72 38.8 ± 5.26
Blotted weight (mg, mean ± SD) 24.2 ± 2.77 22.3 ± 2.50 24.5 ± 1.83 27.5 ± 1.45 35.2 ± 9.30 36.9 ± 4.80
bw (g, mean ± SD) 52.9 ± 6.02 52.0 ± 4.96 51.0 ± 5.77 51.4 ± 4.34 50.3 ± 4.84 50.4 ± 4.42
Absolute ratio  0.92 1.01 1.14 1.45 1.52
bw adjusted ratio 0.93 1.02 1.15 1.44* 1.54*
(Lower CL, upper CL) (0.74, 1.16) (0.82, 1.28) (0.92, 1.44) (1.15, 1.80) (1.23, 1.93)
9 Wet weight (mg, mean ± SD) 34.9 ± 3.47 37.1 ± 6.88 38.8 ± 6.28 46.3 ± 5.79 65.1 ± 9.37 82.8 ± 13.92
Blotted weight (mg, mean ± SD) 34.1 ± 3.67 36.4 ± 6.67 38.1 ± 6.32 45.2 ± 5.89 63.9 ± 9.31 80.5 ± 13.10
bw (g, mean ± SD) 58.0 ± 2.27 58.1 ± 3.84 58.2 ± 3.50 57.1 ± 1.85 58.3 ± 2.75 56.6 ± 2.30
Absolute ratio  1.07 1.12 1.33 1.88 2.36
bw adjusted ratio 1.06 1.11 1.33* 1.86* 2.38*
(Lower CL, upper CL) (0.83, 1.34) (0.88, 1.41) (1.05, 1.70) (1.47, 2.36) (1.87, 3.03)
12 Wet weight (mg, mean ± SD) 26.8 ± 6.97 Not done 32.4 ± 5.92 33.3 ± 14.40 49.1 ± 8.42 Not done
Blotted weight (mg, mean ± SD) 22.4 ± 6.47 27.4 ± 5.34 27.8 ± 15.41 42.5 ± 5.94
bw (g, mean ± SD) 40.4 ± 3.38 43.6 ± 2.47 37.1 ± 7.50 40.2 ± 2.46
Absolute ratio  1.22 1.24 1.95
bw adjusted ratio 1.05 1.31 2.02*
(Lower CL, upper CL) (0.76, 1.44) (0.95, 1.80) (1.49, 2.75)
15 Wet weight (mg, mean ± SD) 33.2 ± 5.56 31.3 ± 5.43 33.5 ± 2.43 30.3 ± 4.50 42.8 ± 9.77 57.0 ± 17.52
Blotted weight (mg, mean ± SD) 28.7 ± 5.47 27.0 ± 3.35 23.5 ± 3.56 24.7 ± 4.08 35.2 ± 7.76 43.8 ± 13.82
bw (g, mean ± SD) 48.3 ± 3.65 49.1 ± 2.49 48.9 ± 2.50 47.3 ± 5.28 48.1 ± 3.89 47.0 ± 2.59
Absolute ratio  0.94 0.82 0.86 1.23 1.53
bw adjusted ratio 0.94 0.82 0.87 1.22 1.52*
(Lower CL, upper CL) (0.70, 1.26) (0.61, 1.10) (0.65, 1.17) (0.91, 1.65) (1.13, 2.05)
18 Wet weight (mg, mean ± SD) 25.0 ± 1.66 20.7 ± 2.82 23.1 ± 2.97 28.2 ± 4.57 52.4 ± 5.42 72.9 ± 6.30
Blotted weight (mg, mean ± SD) 21.3 ± 1.50 19.0 ± 2.42 19.8 ± 3.35 24.9 ± 5.27 41.9 ± 4.00 64.4 ± 6.70
bw (g, mean ± SD) 52.1 ± 3.70 54.4 ± 4.81 56.5 ± 3.86 57.2 ± 4.23 55.2 ± 3.20 58.1 ± 2.54
Absolute ratio  0.89 0.93 1.17 1.97 3.02
bw adjusted ratio 0.88 0.90 1.12 1.93* 2.92*
(Lower CL, upper CL) (0.71, 1.08) (0.72, 1.12) (0.89, 1.40) (1.56, 2.39) (2.32, 3.69)
20 Wet weight (mg, mean ± SD) 57.7 ± 13.08 41.9 ± 20.16 43.8 ± 8.70 45.3 ± 10.93 49.4 ± 12.65 50.5 ± 10.88
Blotted weight (mg, mean ± SD) 54.3 ± 11.77 37.1 ± 8.88 33.7 ± 7.91 37.7 ± 11.77 41.3 ± 10.96 39.0 ± 10.01
bw (g, mean ± SD) 50.7 ± 4.01 51.8 ± 3.00 50.1 ± 3.12 52.2 ± 5.09 51.2 ± 3.16 50.4 ± 1.95
Absolute ratio  0.68 0.62 0.69 0.76 0.72
bw adjusted ratio 0.68 0.62*b 0.68 0.75 0.71
(Lower CL, upper CL) (0.46, 1.0035)c (0.42, 0.91) (0.46, 1.01) (0.51, 1.11) (0.48, 1.05)
21 Wet weight (mg, mean ± SD) 58.0 ± 7.84 84.8 ± 17.77 75.4 ± 15.29 83.2 ± 11.67 82.9 ± 15.24 78.3 ± 20.80
Blotted weight (mg, mean ± SD) 47.3 ± 6.92 66.6 ± 15.54 64.2 ± 16.29 68.2 ± 10.19 75.2 ± 15.77 60.0 ± 15.00
bw (g, mean ± SD) —d —d —d —d —d —d
Absolute ratio  1.39*e 1.34 1.44*e 1.58*e 1.25
bw adjusted ratio —d —d —d —d —d
(Lower CL, upper CL) —d —d —d —d —d
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. bThe recorded decrease in uterine weights from the control vehicle
group was statistically signiﬁcant. cWith the upper 95% conﬁdence limit not < 1.0, the result is not statistically signiﬁcant. dTerminal body weights were not recorded by the laboratory.
eThe blotted uterine weights were analyzed without body weight adjustments and were found to be statistically signiﬁcant. *Level of signiﬁcance, p < 0.05.in both phases 1 and 2 and, in most cases,
with the weak agonists in phase 2 (data not
shown). Combining the observations of
lower variability and the intermittent limited
increase in uterine weights with weak
estrogen agonists, the blotted weight appears
to be the metric of choice.
Despite the excellent overall agreement
among laboratories within protocols, there
was some variability concerning the actual
doses at which statistical signiﬁcance was ﬁrst
achieved. This variability in the dose first
achieving statistical significance was greatest
for BPA in protocols A and B. Here, the dose
range was about 3-fold for protocol A
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Table 19. Uterine weights, body weights, and ratio of the relative increase in uterine weights for NP in protocol C.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (5 mg/kg/day) (15 mg/kg/day) (35 mg/kg/day) (80 mg/kg/day) (100 mg/kg/day)
6 Wet weight (mg, mean ± SD) 115.5 ± 19.84 Not done 123.6 ± 18.60 130.8 ± 8.90 136.7 ± 33.99 Not done
Blotted weight (mg, mean ± SD) 110.7 ± 19.60 112.5 ± 16.77 123.8 ± 12.21 131.2 ± 33.16
bw (g, mean ± SD) 299.6 ± 29.76 300.3 ± 17.75 297.2 ± 14.12 302.6 ± 22.87
Absolute ratio  1.02 1.12 1.19
bw adjusted ratio 1.02 1.14 1.16
(Lower CL, upper CL)a (0.79, 1.30) (0.89, 1.46) (0.90, 1.48)
7 Wet weight (mg, mean ± SD) 75.7 ± 6.68 92.0 ± 12.94 84.4 ± 11.52 96.5 ± 9.82 124.5 ± 20.06 115.5 ± 22.27
Blotted weight (mg, mean ± SD) 73.9 ± 6.58 89.9 ± 12.43 83.0 ± 11.56 94.2 ± 9.67 122.0 ± 18.56 113.5 ± 21.29
bw (g, mean ± SD) 251.5 ± 10.11 252.4 ± 10.26 251.0 ± 15.54 253.0 ± 11.48 252.9 ± 8.20 249.9 ± 10.75
Absolute ratio  1.22 1.12 1.27 1.65 1.54
bw adjusted ratio 1.21 1.12 1.27* 1.64* 1.52*
(Lower CL, upper CL) (0.97, 1.50) (0.90, 1.39) (1.02, 1.58) (1.32, 2.03) (1.22, 1.89)
8 Wet weight (mg, mean ± SD) 86.1 ± 9.20 84.7 ± 10.07 84.8 ± 8.03 99.5 ± 12.82 101.1 ± 7.13 122.2 ± 15.96
Blotted weight (mg, mean ± SD) 82.2 ± 8.89 80.0 ± 9.91 81.2 ± 8.20 94.7 ± 12.02 96.5 ± 7.50 117.0 ± 14.52
bw (g, mean ± SD) 286.7 ± 21.81 291.2 ± 17.60 289.3 ± 18.64 289.3 ± 17.75 290.8 ± 13.88 287.8 ± 15.55
Absolute ratio  0.97 0.99 1.15 1.17 1.42
bw adjusted ratio 0.97 0.98 1.15 1.17 1.42*
(Lower CL, upper CL) (0.81, 1.15) (0.83, 1.17) (0.96, 1.36) (0.98, 1.39) (1.19, 1.67)
9 Wet weight (mg, mean ± SD) 87.2 ± 11.74 86.3 ± 5.17 89.0 ± 14.35 94.5 ± 20.04 106.9 ± 14.18 140.0 ± 22.49
Blotted weight (mg, mean ± SD) 86.3 ± 11.88 85.6 ± 4.91 87.5 ± 14.47 93.4 ± 19.85 105.6 ± 13.74 137.7 ± 21.83
bw (g, mean ± SD) 256.1 ± 8.87 255.3 ± 8.93 260.1 ± 9.96 254.0 ± 11.51 256.1 ± 11.48 254.4 ± 12.33
Absolute ratio  0.99 1.01 1.08 1.22 1.60
bw adjusted ratio 1.00 0.99 1.08 1.23 1.61*
(Lower CL, upper CL) (0.81, 1.24) (0.80, 1.23) (0.88, 1.34) (0.99, 1.52) (1.30, 1.97)
12 Wet weight (mg, mean ± SD) 106.0 ± 18.84 Not done 117.6 ± 18.15 118.1 ± 18.76 146.7 ± 26.86 Not done
Blotted weight (mg, mean ± SD) 98.6 ± 22.04 105.3 ± 17.70 105.1 ± 15.22 129.6 ± 20.50
bw (g, mean ± SD) 297.2 ± 14.54 301.4 ± 15.13 299.1 ± 16.72 297.1 ± 16.15
Absolute ratio  1.07 1.07 1.31
bw adjusted ratio 1.09 1.08 1.33*
(Lower CL, upper CL) (0.83, 1.41) (0.83, 1.41) (1.02, 1.73)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance, p < 0.05.
Table 20. Uterine weights, body weights, and ratio of the relative increase in uterine weights for NP in protocol D.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (5 mg/kg/day) (15 mg/kg/day) (35 mg/kg/day) (80 mg/kg/day) (100 mg/kg/day)
7 Wet weight (mg, mean ± SD) 81.5 ± 12.75 84.9 ± 9.93 88.1 ± 4.53 106.8 ± 11.92 171.8 ± 17.90 158.9 ± 29.05
Blotted weight (mg, mean ± SD) 83.6 ± 13.41 83.0 ± 9.98 85.7 ± 4.94 104.7 ± 12.12 166.9 ± 17.97 154.4 ± 29.48
bw (g, mean ± SD) 272.8 ± 14.89 273.1 ± 15.08 268.9 ± 12.51 267.8 ± 11.72 265.5 ± 11.47 261.3 ± 15.27
Absolute ratio  1.02 1.05 1.29 2.05 1.90
bw adjusted ratio 1.02 1.08 1.31* 2.11* 1.96*
(Lower CL, upper CL)a (0.84, 1.24) (0.88, 1.31) (1.08, 1.60) (1.73, 2.58) (1.60, 2.40)
9 Wet weight (mg, mean ± SD) 76.8 ± 4.59 80.4 ± 9.84 88.0 ± 10.30 106.3 ± 16.24 140.2 ± 14.09 160.6 ± 18.76
Blotted weight (mg, mean ± SD) 75.9 ± 4.97 79.5 ± 10.04 87.3 ± 10.09 105.4 ± 16.29 139.0 ± 13.58 158.0 ± 17.42
bw (g, mean ± SD) 282.1 ± 12.40 282.3 ± 14.46 278.9 ± 13.94 274.9 ± 13.89 271.6 ± 19.50 271.2 ± 12.52
Absolute ratio  1.05 1.15 1.39 1.83 2.08
bw adjusted ratio 1.04 1.15 1.38* 1.83* 2.08*
(Lower CL, upper CL) (0.87, 1.26) (0.95, 1.38) (1.14, 1.66) (1.51, 2.21) (1.71, 2.51)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance p < 0.05.
Table 21. Uterine weights, body weights, and ratio of the relative increase in uterine weights for NP in satellite OVX protocol by oral gavage.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (15 mg/kg/day) (75 mg/kg/day) (125 mg/kg/day) (250 mg/kg/day) (350 mg/kg/day)
12 Wet weight (mg, mean ± SD) 101.1 ± 16.93 Not done 163.5 ± 24.57 179.0 ± 30.90 179.2 ± 15.50 Not done
Blotted weight (mg, mean ± SD) 95.0 ± 16.43 153.8 ± 23.74 168.7 ± 28.77 168.9 ± 16.16
bw (g, mean ± SD) 295.5 ± 11.09 284.5 ± 10.86 283.7 ± 13.93 280.4 ± 11.60
Absolute ratio  1.62 1.77 1.78
bw adjusted ratio 1.60* 1.74* 1.76*
(Lower CL, upper CL)a (1.23, 2.09) (1.34, 2.27) (1.34, 2.32)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance, p < 0.05.(375–1,000 mg BPA/kg/day) and 60-fold for
protocol B (10–600 mg BPA/kg/day),
whereas protocols C and D first achieved
statistical significance at the dose of 100 mg
BPA/kg/day in all studies.
The doses at which the weak estrogen
agonists ﬁrst reach statistical signiﬁcance were
far in excess of those determined for the
potent reference estrogen EE in phase 1. By
oral gavage (protocol A), 16 laboratories
achieved statistical significance in phase 1 at
either 0.3 or 1 µg EE/kg/day (Kanno et al.
2001). By contrast in phase 2, doses of the
weak agonists ranged from 1,000- to 10,000-
fold higher as estimated for MX and shown
for GN, respectively, to over 300,000-fold
higher for BPA. Similar disparities are
observed with sc injection, as statistical signif-
icance with EE was achieved at 0.1 or 0.3 µg
EE/kg/day in phase 1 (Kanno et al. 2001) and
from 5 to 200 mg/kg/day with the weak
agonists in phase 2, including with extended
dosing in protocol D.
As expected for weak estrogen agonists,
the maximum increase in the uterine weights
was also generally less than that observed for
EE in phase 1 of the validation program. The
maximum relative ratio responses of EE-
treated were 4 to 5 in protocol A, 4.5 to 6 in
protocol B, 3.25 to 5 in protocol C, and
approximately 4 in protocol D (Kanno et al.
2003). The maximum uterine weights
reached by the weak estrogen agonists in these
phase 2 studies were route, protocol, and test
substance dependent, as is apparent by com-
paring the data in Figures 1–5.
Differences were found between the routes
of administration in study responsiveness, i.e.,
the dose producing the ﬁrst statistically signiﬁ-
cant increase in uterine weight, from test sub-
stance to test substance. Although many
parties might choose to use the term “sensitiv-
ity” rather than “responsiveness,” validation
experts have used the term sensitivity for a
measure of assay performance: the proportion
of all positive chemicals that are correctly
Mini-Monograph | Kanno et al.
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Figure 4. Ratio of the mean absolute blotted uterine weight in response to doses of NP relative to the vehi-
cle control group. (A) Participating laboratory results for protocol A using immature female rats, dosing by
oral gavage for 3 consecutive days. (B) Participating laboratory results for protocol B using immature
female rats, dosing by sc injection for 3 consecutive days. (C) Participating laboratory results for protocol
C using adult OVX rats, dosing by sc injection for 3 consecutive days. (D) Participating laboratory results
for protocol C using adult OVX rats and extending sc injection dosing to 7 days. In all cases, animals were
humanely sacriﬁced 24 hr after the last dose administration, the uteri were removed and trimmed, and wet
and blotted weights were recorded.
Table 22. Uterine weights, body weights, and ratio of the relative increase in uterine weights for o,p’-DDT in protocol A.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (10 mg/kg/day) (50 mg/kg/day) (125 mg/kg/day) (300 mg/kg/day) (600 mg/kg/day)
3 Wet weight (mg, mean ± SD) 34.6 ± 3.93 44.6 ± 7.09 64.4 ± 4.90 81.3 ± 12.90 101.6 ± 11.55 229.6 ± 65.83a
Blotted weight (mg, mean ± SD) 32.6 ± 4.23 42.5 ± 7.03 62.0 ± 5.06 78.3 ± 12.46 97.3 ± 11.28 104.1 ± 13.22
bw (g, mean ± SD) 63.2 ± 3.07 62.7 ± 2.21 62.7 ± 1.77 60.6 ± 2.96 54.3 ± 9.56 36.1 ± 2.69
Absolute ratiob 1.07 1.57 1.98 2.46 2.63
bw adjusted ratioc 1.09 1.60* 2.04* 2.67* 3.30*
(Lower CL, upper CL)d (0.84, 1.40) (1.24, 2.05) (1.58, 2.63) (1.99, 3.59) (1.80, 6.04)
5 Wet weight (mg, mean ± SD) 45.5 ± 7.68 54.3 ± 11.72 67.3 ± 6.11 87.3 ± 17.05 123.4 ± 40.55e 181.2 ± 9.83e
Blotted weight (mg, mean ± SD) 43.3 ± 7.91 52.5 ± 11.61 65.1 ± 5.43 83.4 ± 15.78 100.3 ± 20.64 123.7 ± 21.57
bw (g, mean ± SD) 58.6 ± 5.07 60.5 ± 2.19 58.2 ± 4.38 55.0 ± 6.53 44.3 ± 11.26 35.0 ± 1.27
Absolute ratio  1.21 1.50 1.93 2.32 2.86
bw adjusted ratio 1.19 1.53* 2.01* 2.71* 3.72*
(Lower CL, upper CL) (0.91, 1.54) (1.18, 1.99) (1.54, 2.63) (1.92, 2.24) (2.24, 6.18)
11 Wet weight (mg, mean ± SD) 29.5 ± 4.35 34.2 ± 3.71 63.7 ± 5.55 67.9 ± 4.38 103.8 ± 31.81 210.3 ± 127.63f
Blotted weight (mg, mean ± SD) 25.3 ± 3.75 31.3 ± 3.87 58.7 ± 5.24 64.2 ± 4.20 87.0 ± 3.90 95.2 ± 5.73
bw (g, mean ± SD) 38.6 ± 3.91 40.6 ± 2.40 41.3 ± 4.01 37.4 ± 2.57 39.5 ± 3.56 28.3 ± 2.30
Absolute ratio  1.24 2.32 2.54 3.44 3.76
bw adjusted ratio 1.21* 2.25* 2.60* 3.43* 4.33*
(Lower CL, upper CL) (1.04, 1.41) (1.94, 2.63) (2.24, 3.01) (2.96, 3.98) (3.35, 5.59)
12 Wet weight (mg, mean ± SD) 24.2 ± 2.48 Not done 61.4 ± 9.24 74.0 ± 14.28 129.2 ± 58.42g Not done
Blotted weight (mg, mean ± SD) 20.6 ± 1.81 54.6 ± 9.03 67.5 ± 14.06 67.4 ± 16.63
bw (g, mean ± SD) 39.7 ± 3.10 40.5 ± 2.54 41.3 ± 5.85 33.0 ± 8.16
Absolute ratio  2.66 3.28 3.28
bw adjusted ratio 2.61* 3.18* 3.45*
(Lower CL, upper CL) (2.01, 3.40) (2.43, 4.15) (2.41, 4.94)
aFour animals died in 600 mg DDT/kg/day group before necropsy. bRatio of arithmetic means of the treated blotted uterine weights relative to the vehicle control blotted uterine weights.
cRatio of geometric means of treated blotted uterine weights relative to the vehicle control blotted uterine weights after adjusting for body weights at necropsy as a covariable. dLower
and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. eOne animal died in 300 mg DDT/kg/day group before necropsy; four animals
died in 600 mg DDT/kg/d group before necropsy. fThree animals died in 600 mg DDT/kg/day group before necropsy. gThree animals died in 300 mg DDT/kg/day group before necropsy.
*Level of signiﬁcance, p < 0.05.Mini-Monograph | OECD uterotrophic bioassay validation: dose–response studies
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Table 23. Uterine weights, body weights, and ratio of the relative increase in uterine weights for o,p’-DDT in protocol B.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (5 mg/kg/day) (25 mg/kg/day) (50 mg/kg/day) (100 mg/kg/day) (200 mg/kg/day)
3 Wet weight (mg, mean ± SD) 34.2 ± 3.49 35.0 ± 3.74 40.8 ± 7.04 40.2 ± 2.19 40.0 ± 3.62 51.3 ± 8.10
Blotted weight (mg, mean ± SD) 31.5 ± 3.97 33.2 ± 3.33 39.0 ± 6.85 38.4 ± 1.82 37.8 ± 3.49 49.5 ± 7.97
bw (g, mean ± SD) 65.4 ± 3.13 65.1 ± 4.32 64.3 ± 3.60 65.2 ± 4.67 64.6 ± 1.70 65.0 ± 2.97
Absolute ratio  1.05 1.24 1.22 1.20 1.57
bw adjusted ratio 0.88 1.03 1.02 1.01 1.31*
(Lower CL, upper CL)a (0.72, 1.08) (0.85, 1.26) (0.84, 1.25) (0.83, 1.23) (1.07, 1.59)
5 Wet weight (mg, mean ± SD) 39.0 ± 10.51 44.2 ± 9.83 41.5 ± 15.56 37.7 ± 8.94 44.3 ± 9.77 53.4 ± 8.45
Blotted weight (mg, mean ± SD) 36.1 ± 10.07 40.5 ± 9.34 38.1 ± 14.74 33.7 ± 8.68 39.5 ± 8.87 48.5 ± 8.89
bw (g, mean ± SD) 57.5 ± 5.69 57.3 ± 4.97 56.7 ± 5.27 56.5 ± 4.62 55.9 ± 6.36 56.7 ± 4.54
Absolute ratio  1.12 1.06 0.93 1.09 1.34
bw adjusted ratio 1.15 1.06 0.97 1.18 1.41*
(Lower CL, upper CL) (0.88, 1.49) (0.82, 1.38) (0.75, 1.27) (0.91, 1.54) (1.09, 1.84)
11 Wet weight (mg, mean ± SD) 27.1 ± 4.15 27.5 ± 3.55 30.6 ± 4.84 27.1 ± 2.09 28.4 ± 2.82 35.8 ± 8.34
Blotted weight (mg, mean ± SD) 23.6 ± 3.87 24.7 ± 3.31 25.7 ± 3.47 24.1 ± 2.18 25.1 ± 2.79 32.9 ± 7.99
bw (g, mean ± SD) 38.6 ± 4.11 38.3 ± 3.34 40.0 ± 3.87 38.1 ± 3.21 38.3 ± 3.50 39.3 ± 3.95
Absolute ratio  1.05 1.09 1.02 1.06 1.39
bw adjusted ratio 1.06 1.06 1.04 1.08 1.36*
(Lower CL, upper CL) (0.85, 1.31) (0.86, 1.32) (0.84, 1.29) (0.87, 1.34) (1.10, 1.68)
12 Wet weight (mg, mean ± SD) 26.8 ± 6.97 Not done 30.8 ± 10.00 37.2 ± 6.82 37.6 ± 10.86 Not done
Blotted weight (mg, mean ± SD) 22.4 ± 6.47 26.3 ± 9.16 31.8 ± 6.26 33.9 ± 10.49
bw (g, mean ± SD) 40.4 ± 3.38 37.6 ± 6.10 42.7 ± 3.54 41.0 ± 5.01
Absolute ratio  1.17 1.42 1.51
bw adjusted ratio 1.33 1.30 1.47*
(Lower CL, upper CL) (0.997b, 1.76) (0.98, 1.72) (1.11, 1.94)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. bWith the lower 95% conﬁdence limit not > 1.0, the result is not con-
sidered statistically signiﬁcant. *Level of signiﬁcance, p < 0.05.
Table 24. Uterine weights, body weights, and ratio of the relative increase in uterine weights for o,p´-DDT in protocol C.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (5 mg/kg/day) (25 mg/kg/day) (50 mg/kg/day) (100 mg/kg/day) (200 mg/kg/day)
3 Wet weight (mg, mean ± SD) 90.8 ± 8.37 101.2 ± 10.13 105.0 ± 6.55 116.6 ± 5.31 126.7 ± 10.92 170.9 ± 37.58
Blotted weight (mg, mean ± SD) 85.5 ± 8.57 96.6 ± 9.84 99.6 ± 6.43 111.1 ± 4.86 122.2 ± 10.32 159.6 ± 27.57
bw (g, mean ± SD) 268.9 ± 8.50 267.3 ± 7.50 266.8 ± 14.01 266.5 ± 12.36 264.3 ± 10.76 256.6 ± 17.51
Absolute ratio  1.12 1.15 1.28 1.41 1.84
bw adjusted ratio 1.13 1.17 1.30* 1.43* 1.86*
(Lower CL, upper CL)a (0.96, 1.33) (0.9899b, 1.37) (1.11, 1.53) (1.21, 1.69) (1.55, 2.21)
11 Wet weight (mg, mean ± SD) 88.9 ± 6.60 87.2 ± 7.21 98.5 ± 8.16 104.9 ± 12.79 103.6 ± 28.85 112.1 ± 18.41
Blotted weight (mg, mean ± SD) 78.5 ± 8.38 75.8 ± 7.10 90.5 ± 7.63 97.1 ± 12.07 99.6 ± 28.59 103.4 ± 15.93
bw (g, mean ± SD) 217.0 ± 5.55 216.2 ± 8.56 217.8 ± 8.86 214.4 ± 9.70 214.6 ± 9.22 212.7 ± 6.96
Absolute ratio  0.97 1.15 1.24 1.27 1.32
bw adjusted ratio 0.97 1.15 1.25 1.25 1.34*
(Lower CL, upper CL) (0.76, 1.23) (0.90, 1.46) (0.98, 1.59) (0.98, 1.59) (1.05, 1.71)
12 Wet weight (mg, mean ± SD) 106.0 ± 18.84 Not done 111.8 ± 22.24 116.6 ± 13.98 136.6 ± 37.63 Not done
Blotted weight (mg, mean ± SD) 98.6 ± 22.04 104.1 ± 20.63 107.9 ± 16.45 128.3 ± 36.21
bw (g, mean ± SD) 297.2 ± 14.54 300.1 ± 21.01 294.3 ± 22.76 301.3 ± 15.35
Absolute ratio  1.06 1.09 1.30
bw adjusted ratio 1.07 1.10 1.31
(Lower CL, upper CL) (0.79, 1.45) (0.81, 1.49) (0.96, 1.78)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. bWith the lower 95% conﬁdence limit not > 1.0, the result is not con-
sidered statistically signiﬁcant. *Level of signiﬁcance, p < 0.05.
Table 25. Uterine weights, body weights, and ratio of the relative increase in uterine weights for o,p’-DDT in protocol D.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (5 mg/kg/day) (25 mg/kg/day) (50 mg/kg/day) (100 mg/kg/day) (200 mg/kg/day)
3 Wet weight (mg, mean ± SD) 89.9 ± 4.86 91.4 ± 10.00 98.0 ± 11.77 104.2 ± 6.70 113.4 ± 9.35 147.7 ± 13.13
Blotted weight (mg, mean ± SD) 86.3 ± 4.86 87.5 ± 9.40 93.8 ± 10.54 100.8 ± 6.21 109.7 ± 9.24 142.5 ± 12.25
bw (g, mean ± SD) 290.6 ± 19.95 289.0 ± 11.66 291.3 ± 18.44 282.5 ± 10.96 282.6 ± 6.80 273.8 ± 14.48
Absolute ratio  1.01 1.09 1.17 1.27 1.65
bw adjusted ratio 0.94 1.01 1.09 1.18* 1.54*
(Lower CL, upper CL)a (0.82, 1.08) (0.88, 1.16) (0.95, 1.25) (1.03, 1.36) (1.34, 1.78)
11 Wet weight (mg, mean ± SD) 84.9 ± 14.40 80.5 ± 7.12 83.6 ± 8.98 102.0 ± 7.79 104.8 ± 5.54 125.0 ± 35.69
Blotted weight (mg, mean ± SD) 71.5 ± 14.84 73.9 ± 6.44 76.7 ± 8.14 93.9 ± 8.43 98.8 ± 5.91 117.6 ± 33.48
bw (g, mean ± SD) 235.0 ± 8.47 233.8 ± 11.51 235.3 ± 12.16 232.9 ± 12.09 224.1 ± 9.60 221.8 ± 11.09
Absolute ratio  1.03 1.07 1.31 1.38 1.64
bw adjusted ratio 1.05 1.08 1.34* 1.48* 1.73*
(Lower CL, upper CL) (0.84, 1.32) (0.87, 1.35) (1.07, 1.68) (1.17, 1.87) (1.36, 2.20)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance, p < 0.05.classified as positive in an assay (ICCVAM
1997). Therefore, the term responsiveness is
used herein. The striking observation was that
these differences in responsiveness were test
substance specific. For BPA, sc injection
achieved statistical signiﬁcance at lower doses
than oral gavage, and the maximum induction
was consistently higher by sc injection.
Likewise for GN, most sc studies achieved sta-
tistical signiﬁcance at a somewhat lower dose,
15 mg GN/kg/day, and with greater consis-
tency than oral gavage. For NP, the majority
of oral gavage and sc studies achieved statisti-
cal significance at similar doses, 75 mg
NP/kg/day and 80 mg/kg/day, respectively.
For MX, the majority of oral gavage studies
achieved statistical significance at the lowest
doses tested and were near their maximum
induction at 20 mg MX/kg/day, whereas sc
injection doses were higher and the maximum
uterine weight increase was lower. For o,p´-
DDT, oral gavage produced statistical signiﬁ-
cance at lower doses and higher maximum
responses. In the sc administration studies, an
overall difference was not discernable between
the intact, immature version (protocol B)
or the adult OVX version (protocol C).
Additionally, the satellite oral gavage studies
using OVX animals produced results similar
to the intact, immature animals in protocol A
in both the maximum fold induction of the
uteri and the ﬁrst dose reaching statistical dif-
ference. Collectively, these results suggest that
no route of administration with various ago-
nists will be consistently the most sensitive.
The substantial equivalence of the results indi-
cates that the choice of route of administration
will then depend on the purpose for which the
assay is used, such as detecting the activity of a
substance at the lowest minimal effective dose
or providing a route of administration relevant
for human and wildlife exposure.
Five dose–response studies of 84 (not
including the two studies in the laboratory
that did not record terminal body weights) did
not observe statistically significant increases
with three substances: NP (three studies), BPA
(one study), and o,p´-DDT (one study). These
three substances are the lowest estrogen recep-
tor–binding affinities, once MX metabolism
in the liver to dihydroxymethoxychlor
(HPTE) is considered (see Table 1 for bind-
ing affinities of each substance, including
HPTE). A closer examination of the circum-
stances and data has been made to see if these
cases were approaching statistical signiﬁcance
or what other circumstances may have inter-
vened to prevent detection of statistical signif-
icance (Table 28). In these studies, statistical
significance is achieved when the lower
95% conﬁdence interval for the mean of the
test substance is > 1.0-fold induction of the
uterine weight.
Given that literature data and expert judg-
ment were used to select the doses; that no
range-ﬁnding studies were performed; that the
range of the doses used was sometimes only a
little more than an order of magnitude; and
that these laboratories did not include the
highest doses in their studies, these few studies
lacking statistical signiﬁcance may have been
anticipated because of program design and not
the performance shortcomings of the bioassay.
In four of five cases, the studies did not test
the highest dose of the ﬁve prescribed doses,
reducing the opportunity for detecting a statis-
tically significant response. These four cases
are examined in detail.
In the ﬁrst case involving NP in protocol
B, the mean control blotted uterine weight in
laboratory 6 was 58.0 mg, where the vehicle
control means in most other immature con-
trol groups were < 40 mg. This would, in the-
ory, be expected to diminish the study’s
responsiveness. Despite this possible impedi-
ment, the lower 95% conﬁdence interval for
the relative ratio for uterine weight increase
was 0.91, indicating that the study was
approaching statistical significance. In com-
parison with other protocol B NP studies, six
of nine studies achieved statistical signiﬁcance
with uterine weight increases at 35 or 80 mg
NP/kg/day, and a seventh achieved statistical
significance at the highest dose of 100 mg
NP/kg/day.
In the second case involving NP in
protocol C, laboratory 6 was again approaching
Mini-Monograph | Kanno et al.
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Figure 5. Ratio of the mean absolute blotted uterine weight in response to doses of o,p’-DDT (DDT) relative
to the vehicle control group. (A) Participating laboratory results for protocol A using immature female rats,
dosing by oral gavage for 3 consecutive days. (B) Participating laboratory results for protocol B using
immature female rats, dosing by sc injection for 3 consecutive days. (C) Participating laboratory results for
protocol C using adult OVX rats, dosing by sc injection for 3 consecutive days. (D) Participating laboratory
results for protocol C using adult OVX rats and extending sc injection dosing to 7 days. In all cases, ani-
mals were humanely sacrificed 24 hr after the last dose administration, the uteri were removed and
trimmed, and wet and blotted weights were recorded.
Table 26. Uterine weights, body weights, and ratio of the relative increase in uterine weights for o,p’-DDT in satellite OVX protocol by oral gavage.
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
Laboratory Measure Vehicle (10 mg/kg/day) (50 mg/kg/day) (125 mg/kg/day) (300 mg/kg/day) (600 mg/kg/day)
12 Wet weight (mg, mean ± SD) 101.1 ± 16.93 Not done 228.1 ± 64.85 472.4 ± 242.66 683.7 ± 143.62 Not done
Blotted weight (mg, mean ± SD) 95.0 ± 16.43 191.2 ± 23.03 253.6 ± 70.91 275.6 ± 31.42
bw (g, mean ± SD) 295.5 ± 11.09 286.1 ± 16.83 278.1 ± 10.52 269.4 ± 3.92
Absolute ratio  2.01 2.67 2.90
bw adjusted ratio 2.03* 2.64* 2.94*
(Lower CL, upper CL)a (1.53, 2.71) (1.92, 3.61) (2.05, 4.23)
aLower and upper 95% conﬁdence limits for ratio of blotted uterine weights based on body weights as a covariable. *Level of signiﬁcance, p < 0.05.Mini-Monograph | OECD uterotrophic bioassay validation: dose–response studies
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Table 27. Laboratory details for animals, diet, vehicles, and bedding.
Strain of rata Animal dieta For oral gavage For sc injection
Laboratory Immature rats OVX rats Immature OVX Vehicle 1 Vehicle 2 Vehicle 1 Vehicle 2 Beddinga
1 Crj;CD(SD)IGS  Crj;CD(SD)IGS  CRF-1, Oriental Yeast CRF-1, Oriental Yeast Corn oil NA Corn oil NA ALPHA-dri (Pulp) for
immature
SPF/VAF SPF/VAF None for OVX
2 Crj:CD(SD)IGS Crj:CD(SD)IGS CRF-1, Oriental Yeast CRF-1, Oriental Yeast Corn oil Ethanol Corn oil Ethanol Arufa-dry for immature
None for OVX
3 Crj:CD(SD)IGS Crj:CD(SD)IGS MF pelleted diet, MF pelleted diet,  Sesame oil Ethanol  Sesame oil Ethanol  Autoclaved
hardwood chips, Beta 
Oriental Yeast Oriental Yeast (99.5%) (99.5%) Chips, for immature and
OVX
4 CRL: WI (GLX/BRL/  NA Kliba rat/mouse/  NA Olive oil  Olive oil  NA NA SSNIFF (type 3/4)
HAN) IGS BR hamster, Provimi EP/DAB EP/DAB
5 CRL: CD (SD)  NA PMI certiﬁed rodent  NA Ethanol Corn oil NA NA ALPHA DRI for immature
IGSBR diet 5002 (95%) DACB PAPER for OVX
6 Crl CD® (SD) Crl  CD® (SD)  A04 C pellet  A04 C pellet  NA NA Corn oil NA Autoclaved sawdust for
IGS BR IGS BR maintenance diet, maintenance diet, immature and OVX
UAR UAR
7 Crj:CD(SD)IGS Crj:CD(SD)IGS CE-2, CLEA CE-2, CLEA Corn oil NA Corn oil NA No bedding used for
immature or OVX
8 Alpk:APfSDb Alpk:APfSD R&M3 to weaning  R&M1, Peanut oil  NA Peanut oil  NA Shredded paper for
R&M1 postweaning, Special Diet Services (arachis oil) (arachis oil) immature and OVX
Special Diet Services
9 Crj: CD (SD) IGS Crj: CD (SD) IGS MF pelleted diet,  MF pelleted diet,  Olive oil Ethanol Olive oil Ethanol Sunﬂake for immature
Oriental yeast Oriental yeast (99.5%) (99.5%) and OVX
11 Wistar  Wistar  CE-2, CLEA CE-2, CLEA Corn oil NA Corn oil NA Sunﬂake for immature
(BrlHan: (BrlHan: None for OVX
WIST@Jcl) WIST@Jcl)
12 Crl:CD®(SD) Crl:CD®(SD) PMI certiﬁed rodent  PMI certiﬁed rodent  Corn oil NA Corn oil NA Ground corncobs “Bed-
IGS BR IGS BR diet 5002 diet 5002 O’Cobs” 
for immature and OVX
13 SPF-bred Wistar,  NA Altromin 1324,  NA Corn oil plus  NA Corn oil plus  NA Low-dust wood granules 
HSD/Cpb: WU Altromin min. ethanol min. ethanol Type BK 8/15
14 SD ICO:OFA SD  NA Pellet AO4C 10, NA Corn oil NA Corn oil NA UAR
(IOPS Caw) UAR
15 Wistar Hsd  NA R&M3, NA NA NA Corn oil plus  NA No bedding used
Cpb:WU Special Diet Services min. ethanol
18 Sprague-Dawley NA PMI certiﬁed rodent  NA NA NA Corn oil plus  NA Elm tree (autoclaved)
diet 5014 min. ethanol
20 Hsd: Sprague  NA Altromin MT,  NA NA NA Corn oil 10%  Nesting material
Dawley Altromin ethanol
21 Crl:CD(SD)BR NA GLP4RF25 top  NA NA NA Corn oil NA Dust-free poplar/ﬁr wood
certiﬁcate, Mucedola chips, heat processed
Abbreviations: min., minimal; NA, not applicable. 
aDetailed information is available from the corresponding author of this article. bWistar-derived strain that is Sprague-Dawley (SD) fostered.
Table 28. Data for laboratories that did not observe a statistically signiﬁcant increase in uterine weights with treatment. 
Doses
Laboratory Substance Protocol Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Comments
6N PB 5 mg/kg/daya 15 mg/kg/day 35 mg/kg/day 80 mg/kg/day 100 mg/kg/day Five labs performing the NP dose response 
Not done 0.84 1.03 1.24 Not done reached statistical signiﬁcance only at dose 
(0.62, 1.13) (0.76, 1.40) (0.91, 1.69) 4 and a sixth only at dose 5 (100 mg/kg/day).
6N PC 5 mg/kg/day 15 mg/kg/day 35 mg/kg/day 80 mg/kg/day 100 mg/kg/day One of ﬁve labs performing the NP dose 
Not done 1.02 1.14 1.16 Not done response reached statistical signiﬁcance 
(0.79, 1.30) (0.89, 1.46) (0.90, 1.48) only at dose 4 and two others only at dose 5 
(100 mg/kg/day).
12 DDT C 5 mg/kg/day 25 mg/kg/day 50 mg/kg/day 100 mg/kg/day 200 mg/kg/day One of the other two labs performing the 
Not done 1.07 1.10 1.31 Not done DDT dose response did not reach statistical
(0.79, 1.45) (0.81, 1.49) (0.96, 1.78) signiﬁcance until dose 5 (200 mg/kg/day).
12 BPA Satellite 60 mg/kg/day 200 mg/kg/day 375 mg/kg/day 600 mg/kg/day 1000 mg/kg/day With immature animals, one of four labs 
C by po Not done 1.16 1.27 1.29 Not done performing the BPA dose response reached
(0.86, 1.56) (0.97, 1.68) (0.94, 1.75) statistical signiﬁcance only at dose 4 and a
second only at dose 5 (1,000 mg/kg/day). 
20 NP B 5 mg/kg/day 15 mg/kg/day 35 mg/kg/day 80 mg/kg/day 100 mg/kg/day Five laboratories performing NP dose response 
0.68 0.62 0.68 0.75 0.71 reached statistical signiﬁcance only at dose 4
(0.46, 1.00) (0.42, 0.91) (0.46, 1.01) (0.51, 1.11) (0.48, 1.05) (80 mg/kg/day) and a sixth only at dose 5 (100
mg/kg/day). In this case, the mean vehicle
blotted uterine weights were greater than the
means of all treated groups, as can be seen in
the columns.
aFirst row: treatment dose of the given chemical. Second row: mean relative increase in blotted uterine weight of treatment versus vehicle controls. Third row: (lower, upper 95% conﬁ-
dence intervals).statistical significance, with a lower 95%
conﬁdence interval of 0.90. Two other proto-
col C NP studies out of ﬁve had not achieved
statistical significance at 80 mg NP/kg/day,
but both of these laboratories then did so at
the highest dose in the series of 100 NP
mg/kg/day. The maximum inductions at the
80-mg NP/kg/day dose in other protocol C
NP studies had relatively low ratio values of
1.2 to 1.65. Again, the control uterine weights
in laboratory 6 were higher than average,
potentially reducing responsiveness.
In the third case involving DDT in
protocol C, laboratory 12 was close to achiev-
ing statistical significance at 100 mg
DDT/kg/day, with a lower 95% confidence
interval of 0.96 (Table 24). The maximum
induction in uterine size at this dose in other
DDT studies using sc administration was low:
1.3–1.5 (Tables 23, 24, and 25). One other
study using OVX animals had not achieved
statistical signiﬁcance at this dose, but did so at
the highest dose in the series of 200 mg
DDT/kg/day.
In the fourth case involving BPA, the
satellite oral gavage study with OVX animals
approached statistical signiﬁcance at the dose
of 600 mg BPA/kg/day, with the lower 95%
confidence interval value of 0.94 (Table 6).
For comparison, one of four protocol A BPA
laboratories required the highest dose of
1,000 mg BPA/kg/day to achieve statistical
signiﬁcance (Table 2).
In retrospect, the several cases lacking or
having borderline significance appear to be
one of the doses selected and not one of the
performance capabilities of the uterotrophic
bioassay. For example, the doses selected
apparently were too low and were too nar-
rowly spaced for both the immature and the
OVX versions in the case of the sc doses of
NP and DDT (see Figures 4 and 5, respec-
tively). Important conclusions from these
observations are that range-finding studies
should be considered when working with
unknown test substances, and that a more
widely interspersed set of doses could be used,
for example, spacing at 0.5-log intervals, as
was done with EE in phase 1, so that five
doses would cover two orders of magnitude.
In addition, the range-ﬁnding studies may be
useful in avoiding conditions that exceed the
maximum tolerated dose.
One final case deserves examination.
There was a second instance in protocol B
where NP failed to achieve statistical signiﬁ-
cance. First, in this case, the control blotted
uterine weight mean in laboratory 20 was
54.3 mg, which again would be expected to
diminish responsiveness. Analysis of this labo-
ratory’s diet showed that the phytoestrogen
content measured by combined GN,
daidzein, and coumestrol was greater than
500 µg/g diet (Owens et al. 2003). Second,
the blotted uterine weight means of all NP
test-substance dose groups were less than the
controls, ranging from 37.1 mg to 41.3 mg,
even up to the highest NP doses. Third, this
was the laboratory with the mirror opposite
BPA dose response showing statistical signiﬁ-
cance at the two lowest BPA doses and even
statistically significant decreases at the two
highest doses, i.e., the upper 95% conﬁdence
levels were < 1. Fourth, this laboratory had
not participated in phase 1 or previously
demonstrated its proficiency to conduct the
protocol with a set of reference EE doses. It
must, therefore, be concluded that the results
in this laboratory for BPA and NP are an
anomaly and cannot be attributed to the
inherent performance capabilities of the spe-
cific protocol or the uterotrophic bioassay
in general.
In these studies, the uterotrophic results
from protocol A using oral gavage appear to
relevant and conservatively predictive when
compared with available chronic data
from dietary studies. NP was negative at
15 mg/kg/day in all laboratories and positive
at 75 mg/kg/day (Table 17). This compares
favorably with LOEL observations of about
35 mg/kg/day in two multigeneration studies
(Chapin et al. 1999; Nagao et al. 2001). BPA
was negative at 200 mg/kg/day in all laborato-
ries and was positive over a range of
375–1000 mg/kg/day. This compares favor-
ably with the absence of estrogen-mediated
effects at doses up to 500 mg/kg/day, as well
in the controversial low–dose range in two
multigeneration studies (Ema et al. 2001; Tyl
et al. 2002). The GN and MX uterotrophic
results in protocol A are also consistent when
compared with available developmental and
other studies (Casanova et al. 1999; Chapin
et al. 1997; Newbold et al. 2001).
In conclusion, both the intact immature
and the OVX uterotrophic versions of the
uterotrophic bioassay and all protocols appear
robust, reproducible, and transferable across
laboratories. They are able to detect weak
estrogen agonists where sufficient doses are
administered and control uterine weights are
sufficiently low to provide responsiveness.
These results will be submitted along with
other data for independent peer review to pro-
vide support for the validation of the
uterotrophic bioassay. These results will also be
used to develop a draft OECD test guideline
for the uterotrophic bioassay. Subsequently,
the guideline will be available for acceptance
and implementation by regulatory authorities.
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